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Glioblastoma multiforme (GBM) is the most common and aggressive primary brain 
tumor with poor prognosis due in part to drug resistance and high incidence of tumor 
recurrence. The drug resistant and cancer recurrence phenotype may be ascribed to the 
presence of glioblastoma stem cells (GSCs), which seem to reside in special stem-cell niches 
in vivo and require special culture conditions including certain growth factors and serum-
free medium to maintain their stemness in vitro. Exposure of GSCs to fetal bovine serum 
(FBS) can cause their differentiation, the underlying mechanism of which remains unknown. 
Reactive oxygen species (ROS) play an important role in normal stem cell differentiation, 
but their role in affecting cancer stem cell fate remains unclear. Whether the metabolic 
characteristics of GSCs are different from other glioblastoma cells and can be targeted are 
also unknown.  
vii 
 
In this study, we used several stem-like glioblastoma cell lines derived from clinical 
tissues by typical neurosphere culture system or orthotopic xenografts, and showed that 
addition of fetal bovine serum to the medium induced an increase of ROS, leading to 
aberrant differentiation and decreases of stem cell markers such as CD133. We found that 
exposure of GSCs to serum induced their differentiation through activation of mitochondrial 
respiration, leading to an increase in superoxide (O2-) generation and a profound ROS stress 
response manifested by upregulation of oxidative stress response pathway. This increase in 
mitochondrial ROS led to a down-regulation of molecules including SOX2, and Olig2, and 
Notch1 that are important for stem cell function and an upregulation of mitochondrial 
superoxide dismutase SOD2 that converts O2- to H2O2. Neutralization of ROS by antioxidant 
N-acetyl-cysteine in the serum-treated GSCs suppressed the increase of superoxide and 
partially rescued the expression of SOX2, Olig2, and Notch1, and prevented the serum-
induced differentiation phenotype. Additionally, GSCs showed high dependence on 
glycolysis for energy production. The combination of a glycolytic inhibitor 3-BrOP and a 
chemotherapeutic agent BCNU depleted cellular ATP and inhibited the repair of BCNU-
induced DNA damage, achieving strikingly synergistic killing effects in drug resistant GSCs. 
This study uncovers the metabolic properties of glioblastoma stem cells and suggests 
that mitochondrial function and cellular redox status may profoundly affect the fates of 
glioblastoma stem cells via a ROS-mediated mechanism, and that the active glycolytic 
metabolism in cancer stem cells may provide a biochemical basis for developing novel 
therapeutic strategies to effectively eliminate GSCs.  
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INTRODUCTION 
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1. CANCER STEM CELL 
Cancer stem cells (CSCs) are a sub-population of rare malignant cells which have a 
capability for indefinite proliferation, continuous self-renewal and multi-lineage 
differentiation (1). Although the existence of CSCs was first proposed over fifty years ago 
(2), only in the last two decades have these cells been discovered in hematological 
malignancies. Leukemia stem cells (LSCs) have been identified in both mice and patients 
with acute myeloid leukemia (AML) (3, 4). CD34+ CD38- AML cells can engraft severe 
combined immune-deficient (SCID) mice to produce large numbers of colony-forming 
progenitors; however, CD34+ CD38+ and CD34- AML cells don’t have this property (5). 
Since then, CD34+CD38- have been utilized as markers for enriching LSCs (3). Other stem 
cell markers including CD123+ (6) and Hoechst33342low (7) are also identified in AML. 
Additionally, CSCs have been identified in solid tumors of breast and brain. CD44+CD24-
/lowLineage- breast cancer cells and CD133+ brain tumor cells can self-renew and 
differentiate to produce a phenotype identical to the initial tumor (8, 9). A large quantity of 
recent studies have also indicated the existence of CSCs in different types of solid tumors 
(10, 11) such as colon (12), pancreatic (13), prostate (14), and liver cancer (15).  A number 
of cell surface markers including prominin-1 (CD133), CD44, aldehyde dehydrogenase 1 
(ALDH1), epithelial-specific antigen (ESA) and a fluorescent dye Hoechst33342  have been 
proven useful for isolating CSCs (Table 1) (11). 
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Table 1. Cancer stem cell markers in different tumors. 
Cancer Type Markers References 
Brain Tumor CD133+, Nestin+, Hoechst33342 exclusion (9, 16, 17) 
Breast Cancer CD44+CD24-/low, Oct4+, CX43-, ALDH1+ (8, 18-20) 
Acute Myeloid Leukemia CD34+CD38-, CD123+, Hoechst33342 exclusion (3, 6, 7) 
Multiple Myeloma CD138-,CD19+ (21, 22) 
Colon Cancer CD133+, ESAhi/CD44+, ALDH1+ (12, 23, 24) 
Prostate Cancer CD133+ (25) 
Hepatic Cancer CD133+, CD90+ (26) 
Lung Cancer CD133+ , Hoechst33342 exclusion (27, 28) 
Head & Neck Cancer CD44+ (29) 
Pancreatic Cancer CD44+CD24+ ESA+, CD133+CXCR4+ (13, 17, 30) 
Melanoma ABCB5+ (31) 
Ovarian Cancer CD44+CD177+, Hoechst33342 exclusion (32, 33) 
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There is growing evidence indicating that CSCs are crucial to tumor initiation and 
maintenance, while the origin of CSCs remains elusive. Since CSCs display normal stem 
cell features: the ability to self-renew and differentiate, either tissue stem cells or bone 
marrow stem cells have been identified as the cells of origin for cancer. Barker et al have 
shown that Apc deletion in long-lived intestinal stem cells (Lgr5+) led to malignant 
transformation (34). Oncogenic K-ras transformation or p53 mutation can stimulate 
bronchioalveolar stem cell expansion, which is related to lung adenocarcinoma initiation (35, 
36). In addition, bone marrow stem cells can be recruited into stomach and give rise to 
gastric cancer under chronic infection of Helicobacter pylori (37). However, a number of 
studies suggest that malignant tumors can be initiated in differentiated cells. Not only neural 
stem cells (NSCs) but also astrocytes can be induced into glioma by combined loss of p16 
(INK4a) and p19 (ARF) (38, 39). But neurofibromin deficiency only cause tumor in 
differentiated glia cells instead of neural crest stem cells (40). It remains controversial 
whether CSCs origin from normal stems cells or differentiated cells. They may rise from 
normal stem cells or progenitor cells through mutations or they may be derived from 
differentiated cells through dedifferentiation (41, 42). 
Although CSCs may constitute a small fraction of the total cancer cells in the tumor 
bulk, this special subpopulation is thought to play a major role in cancer resistance to 
chemotherapy and radiotherapy, leading to persistence of residual disease and cancer 
recurrence (43). This phenomenon is due in part to the unique biological properties of CSCs 
including high capacity of DNA repair, high expression of certain ATP-dependent drug 
exporting pumps, high levels of glutathione synthesis, and high expression of cell survival 
factors (44-46). On one hand, CSCs preferentially activate the DNA damage checkpoint 
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response after radiation that can repair radiation induced DNA damage more efficiently than 
non-CSCs (47). On the other hand, CSCs can pump out many chemotherapeutic agents 
through ATP-binding cassette (ABC) transporters, which contribute to their chemotherapy 
resistance (48). Additionally, compared to non-CSCs, CSCs show a significant 
overexpression of glutathione synthesis enzymes that might be responsible for 
chemotherapy and radiation resistance (46, 49).  
A detailed understanding of the factors that affect the ability of CSCs to maintain 
their stemness is important for the development of new strategies to effectively eliminate 
cancer stem cells or to induce their differentiation. Nevertheless, there are very limited 
therapeutic strategies that are effective in eliminating CSCs currently, keeping CSCs a major 
challenge in cancer treatment.  
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GLIOBLASTOMA STEM CELL 
Glioblastoma multiforme (GBM), a WHO grade IV astrocytoma, is the most 
common and aggressive primary brain tumor in adults. Although maximal surgical resection, 
radiotherapy, and chemotherapy are performed in patients with this brain cancer, the 
treatment outcomes are still unsatisfactory, with median survival durations of only 12-15 
months and the 5-year survival rates of less than 10% (50, 51). Previous studies 
demonstrated that glioblastoma stem cells (GSCs) promote chemoresistance and 
radioresistance, which are likely responsible for the recurrence of GBM (47, 52-54). Several 
markers have been identified for isolating GSCs, among which CD133 is the most widely 
used one. CD133, a cell surface glycoprotein containing five trans-membrane domains and 
two glycosylated extracellular loops, was first identified in hematopoietic stem cells (55). 
High levels of CD133 expression have been found in various stem and progenitor cell 
populations including GBM. CD133+ subpopulation of brain tumor cells have CSC 
properties (9) and only these cells but not the CD133- cells are capable of tumor initiation 
when inoculated into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) 
mouse brains (56). Another CSC marker Hoechst 33342, a fluorescent DNA binding dye, 
was also applied to GBM (57, 58). The GSCs are isolated as the side population based on 
the ability of cells to pump out Hoechst 33342 through the verapamil-sensitive ATP binding 
cassette transporter (59). However, all of these GSC markers were challenged by some 
studies. CD133-negative glioblastoma cells are also able to initiate tumors (60, 61) and side 
population is not necessary for identifying GSCs (62). 
Long-term expansion of GSCs has been possible in neural sphere culture which was 
previously established for isolating neural stem cells and progenitor cells (63). The neural 
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sphere culture contains no serum and is supplemented with growth factors EGF and FGF2, 
and additional mitogens or antioxidants. This serum-free culture system is successful to 
isolate GSCs with long term self-renewal and tumorigenic potential (64, 65), and it closely 
mimics the phenotype and genotype of parental GBM than serum-containing culture (66). 
However, adding serum into the neural sphere culture can cause irreversible differentiation 
of neural stem cells (67, 68).  
Like other CSCs, GSCs have been found to be resistant to all kinds of treatments. 
GSCs display a marked resistance to commonly used chemotherapeutic agents and are able 
to recover and proliferate after drug treatment (69). GSCs can also be enriched after 
radiation or in recurrent GBM when compared with primary GBM, which might be 
attributed to GSCs’ efficient activation of the DNA damage response (70, 71). Additionally, 
recent studies have suggested that hypoxic environment play critical roles in the 
maintenance of GSC population (72-74). The hypoxic niches may further promote drug 
resistance, which makes targeting GSCs more difficult. Some novel compounds have been 
found to be effective to kill GSCs including debromohymenialdisine, an inhibitor of 
checkpoint kinases, which can reverse the radioresistance of GSCs (70) and cyclopamine, a 
Hedgehog pathway inhibitor, which can decrease GSCs and block tumor formation (75).  
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MICROENVERIONMENT 
Normal stem cells reside in some physiologically limited and specialized 
microenvironment, which is named stem cell niche (76). The stem cell niche is the sum of 
all cell-cell and cell-extracellular matrix interactions and controls normal asymmetrical 
division of stem cells by maintaining a balance between self-renewal and differentiation. 
Brain stem cells reside in the vascular rich subventricular zone and subgranular layer (77). 
It’s likely that vascular-derived factors including brain-derived neurotrophic factor (BDNF), 
vascular endothelial growth factor C (VEGFC) and pigment epithelium-derived factor can 
regulate neural stem cell function (78). Other cell types such as ependymal and transit 
progenitor cells are also likely to regulate NSCs. The interaction of NSCs and their niche is 
not unidirectional. NSCs may modulate the stem cell niche and induce angiogenesis by 
increasing the expression of VEGF and BDNF in endothelial cells (79).  
Recently, a CSC niche that has a similar role as normal stem cell niche has been 
proposed (80) and supported by emerging evidence. Like normal stem cells, CSCs depend 
on a permissive microenvironment to retain their self-renewal abilities and give rise to more 
differentiated cells (81). CSCs seem to reside in a hypoxic niche due to aberrant blood 
vessel formation and rapid cell growth (82). Hypoxia has been found to functionally 
promote the self-renewal ability of GSCs (73) and increase the expression of CD133 (83) 
and side population signature genes in glioblastoma cell lines (84, 85). These effects of 
hypoxia are likely mediated by HIF-1α or HIF-2 (84, 85).  Knocking down HIF1α or HIF2α 
can not only lead to reduced cell growth and survival in GSCs in vitro but also result in 
decreased tumorigenic capacity and increased survival of mice in vivo (86).  
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Stem cells of brain tumors including GBM have been found within vascular niches 
and the relationship between CSCs and endothelial cell is reciprocal (Figure 1). On one hand, 
the vascular endothelial cells can maintain brain tumor cells in a stem-like state and 
accelerate the tumor initiation and growth when co-transplanted in mice brain (87). 
Endothelial cells directly provide Notch ligands (88) or release nitric oxide to neighboring 
CSCs (89), activating the Notch pathway in CSCs. On the other hand, CSC can promote the 
endothelial cell growth and vessel formation. CD133+ glioma stem cells, but not CD133- 
glioma cells, cause highly proliferative and angiogenic tumors when implanted into mice 
brains, and they also secret 10 to 20 folds more VEGF than CD133- glioma cells in vitro 
(70). Treating CD133+ glioblastoma cells with a VEGF antibody, bevacizumab which binds 
to VEGF-A ligand to prevent endothelial cell receptor activation, can inhibit their 
proangiogenic effects on endothelial cell (migration and tube formation) and initiate tumors 
in xenografts (70).  
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Figure 1. Glioblastoma stem cells reside within a hypoxia and perivascular 
niche. The GSC niche is composed of tumor blood vessels, stromal cells and 
extracellular matrix. GSCs remain quiescent in hypoxic niches, but create 
vascular niches in order to proliferate. On one hand, GSCs stimulate the 
growth of neovasculature by expressing growth factors such as VEGF. On the 
other hand, tumor blood vessels create a vascular niche to help maintain GSCs. 
GF: growth factors; GSC: glioblastoma stem cell; OGC: other glioblastoma 
cell; SC: stromal cell; TBV: tumor blood vessels.  
11 
 
ABERRANT DIFFERENTIATION 
Glioblastoma grown from cancer stem cells contains mixed populations of cancer 
stem cell, progenitor cell and heterogeneous cell types. Besides self-renewal, GSCs can be 
induced to differentiate into all neuronal lineages expressing the markers of neuronal, 
astroglial or oligodendroglial cells (90). GSCs are also able to differentiate into functional 
endothelial cells in vivo (91). Since the differentiation of GSCs is not tightly regulated like 
in NSCs, it’s difficult to categorize glioblastoma cells according to the hierarchical pyramid 
of normal development (90). However, most of studies have applied the markers based 
differentiation criteria of NSCs to GSCs.  
Fetal bovine serum (FBS) or all-trans-retinoic acid (ATRA) treatment can rapidly 
cause GSC morphology change, dramatically decrease NSC markers and induce lineage-
specific differentiation markers (92, 93). Culturing under serum condition results in a loss of 
NSC markers, a gain of glial or neuronal markers, and a decrease of tumorigenicity (94). 
ATRA which has been proven to be a powerful antitumor agent in acute promyelocytic 
leukemia can induce differentiation and cell death in GSCs (94, 95). It can also inhibit the 
tumor growth in xenograft mice, which is likely mediated by Notch pathway (92). 
Interference with other molecules or pathways is also able to induce differentiation. For 
instance, inhibition of Bmi1 and glycogen synthase kinase 3 beta (GSK3β) activity increases 
differentiation markers and reduces colony formation in glioblastoma cells (96). 
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2. REACTIVE OXYGEN SPECIES 
Reactive oxygen species (ROS) are a group of highly reactive oxygen-containing 
species that include superoxide (O2-), singlet oxygen (1O2), hydrogen peroxide (H2O2) and 
the hydroxyl free radical (.OH) (97). ROS production is a cascade of reactions that usually 
begins with the generation of superoxide (98). Mitochondrial electron transport chain (ETC), 
the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) complex, and 
the endoplasmic reticulum (ER) system have been recognized as major generators of cellular 
ROS (Figure 2). Mitochondrial ETC produces O2- as a by-product of cellular metabolic 
pathway through passing electrons to O2 (99). Among the five components of ETC, complex 
I and complex III are the major sites for ROS formation (99). Another major source of 
cellular ROS is the NOX, a membrane-bound enzyme complex, that generates superoxide 
by transferring electrons from NADPH to O2 (100). The other primary generator for ROS is 
the ER, which is overcrowded with a number of enzymes (NOX, flavin monooxygenases, 
gulonolactone oxidase and cytochrome P450 isoenzymes) that can produce superoxide or 
hydrogen peroxide as by-products of the reactions (101-104).  
Because ROS interact non-specifically with lipids, proteins and nucleic acids, 
causing lipid peroxidation, protein oxidation and DNA mutations, respectively (105), they 
were initially considered to be harmful. Later studies found that ROS also play an important 
role in cell proliferation, apoptosis and signaling (Figure 3) (100). ROS have a multitude of 
effects on cell cycle progression, of which depends upon the amount of ROS, the type of 
ROS, and the duration of exposure of the cells to ROS (106). A short exposure of non-
proliferating cells to moderate ROS may stimulate proliferation. Prolonged exposure to low 
ROS results in differentiation. For instance, ROS generated from complex III is required to 
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initiate the differentiation of human mesencymal stem cells into adipocytes. Disruption of a 
bHLH transcription factor, UPB1, which directly regulates the expression of a set of 
antioxidant enzymes peroxidases, leads to a delay in the onset of differentiation (107). If the 
amounts of ROS are high or the exposure to ROS is long, cells will arrest in all phases and 
undergo apoptosis (106). ROS increase induces the expression of cyclin kinase inhibitor p21, 
the inhibition of CDK2, the expression of Chk1 and the decrease of Cdc25c, which lead to 
subsequent G1 phase, S phase and G2/M phase arrest respectively (106). Besides its role in 
cell cycle progression, ROS also performs as intracellular messengers and affect different 
transcription factors and intracellular signaling pathways (100). Low levels of ROS induce 
Nrf2, a transcription factor coding for the antioxidant enzymes (108). Intermediate amount 
of ROS triggers the activation of two transcription factors, nuclear factor-ĸB (NF-ĸB) and 
activator protein (AP)-1 (109). H2O2 can activate NF-ĸB, making it dissociate from IĸB and 
translocate to the nucleus (110).  H2O2 can also upregulates AP-1 activity through ERKs, 
JNKs and p38 (111). ROS can also participate in signal transduction pathways through 
activating mitogen-activated protein kinases (MAPK) pathway (112) and Janus kinase/signal 
transducers and activators of transcription (JAK/STAT) pathway (113). However, high 
amount of ROS induces opening of the mitochondrial permeability transition pore, leading 
to apoptosis (114). 
14 
 
 
 
Figure 2. Major sources of cellular ROS. Mitochondrial electron transport 
chain, NADPH oxidase (NOX) complex, and the endoplasmic reticulum (ER) 
system are primary generators for ROS. 
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Figure 3. ROS levels and cell status. Quiescent cells maintain low 
levels of ROS. An intermediate increase of ROS induces Nrf-2, NF-ĸB 
and AP-1 signaling, and triggers cell proliferation.  A high amount of 
ROS induces perturbation of mitochondrial permeability transition pore 
(Mito PT pore), leading to apoptosis or necrosis. 
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ROS IN CANCER 
ROS may be a driving force for cancer initiation and progression. DNA damage and 
mutation caused by ROS are considered as a major cause of cancer (115). Most of ROS-
induced mutations seem to involve modification of guanine, causing G→T transversions 
(116-118). If oncogenes or tumor suppressor genes are related, the mutation can result in 
cancer initiation or progression (115). As an evidence, extensive oxidative modifications in 
DNA has been observed in cancers (119), in which the hydroxylation of guanine in the 8-
position (8-OHdG) is the most frequent and most mutagenic lesion. Cigarette smoke can 
cause the accumulation of 8-OHdG, which causes lack of base pairing specificity and 
misreading of the modified base and adjacent residues, thus leading to breast cancer and 
liver cancer (115). Sustained ROS may also trigger epithelial–mesenchymal transition 
(EMT), invasion and migration in cancer cells (120). Repeated treatment with a low dose of 
H2O2 in mammary epithelial cells results in EMT like morphology transformation and 
invasiveness (121). ROS can also induce urokinase plasminogen activator receptor 
expression and stimulate gastric cancer cell invasiveness and metastasis (122). 
Compared with normal cells, cancer cells have shown increased levels of ROS (123-
125). ROS generation is induced after the expression of several oncogenes including H-Ras 
and c-Met (126-128). The mitochondrial DNA with mutations from highly metastatic tumor 
cell line can confer high metastatic potential to poorly metastatic cell line, which is likely 
mediated by ROS overproduction and can be blocked by a ROS scavenger N-acetylcysteine 
(NAC) (129). Since cancer cells have shown increased ROS status, further increasing ROS 
may make them more vulnerable to the damage than normal cells (130). Compounds which 
promote ROS generation in cancer cells have shown promising anticancer activities. 
17 
 
Elesclomol, a compound that increases ROS production, has shown therapeutic activity in 
melanoma  (130). Other compounds which interfere with the antioxidant, glutathione have 
also shown effectiveness in cancer therapy. Both phenethyl isothiocyanate (PEITC) and 
buthionine sulphoximine (BSO) can lead to a decrease of cellular GSH, causing cancer cell 
death (131, 132). 
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ANTIOXIDANT SYSTEM 
Cells are capable of keeping themselves in an oxidation-reduction reactions (redox) 
homeostasis state because of several antioxidant defenses including ROS-scavenging 
enzymes and small scavenger molecules (133). There are three major intracellular ROS-
scavenging enzymes: superoxide dismutases (SOD), catalases and peroxidases (Figure 4). 
The SODs that convert superoxide to hydrogen peroxide are the first and most important 
line of antioxidant enzymes against ROS (134). Three distinct isoforms of SOD have been 
identified in mammals: SOD1 (CuZn-SOD), SOD2 (Mn-SOD), and SOD3 (Ec-SOD) (135). 
The primary locations of SOD1, SOD2 and SOD3 are cytoplasm, mitochondria and outside 
of cytoplasm respectively. Catalases and peroxidases catalyze the reaction of hydrogen 
peroxide into water.  Peroxidases include glutathione peroxidase (GPX), peroxiredoxin 
(PRX), thioredoxin (TRX), thioredoxin reductase (TR), glutaredoxin (GRX), sulfiredoxin 
and sestrin. GPx is the most prominent of them. 
The intracellular non-enzymatic antioxidants are composed of vitamins like vitamin 
C, vitamin E, proteins like β-carotene, albumin and GSH (136). GSH is present in 
millimolar concentrations in cells and is the major component in maintaining redox 
homeostasis. GSH is synthesized by two enzymes, γ-glutamylcysteine synthetase (γ-GCS), 
which is the rate-limiting enzyme, and glutathione synthetase (137).  
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Figure 4. Three major ROS-scavenging enzymes in cells: superoxide 
dismutases (SOD), catalases and peroxidases. SOD, superoxide dismutases; 
CAT, catalase;  TRX, thioredoxin; GRX, glutaredoxin; PRX, peroxiredoxin; GPx, 
glutathione peroxidase; GR, glutathione reductase; GSH, glutathione; GSSG, 
oxidized glutathione; G6PDH, glucose-6 phosphate dehydrogenase. 
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Nuclear factor E2-related factor 2 (Nrf2), a basic leucine zipper transcription factor 
that controls the genes coding for antioxidant enzymes, plays a crucial role in protecting 
cells against oxidative stress. Phosphorylation of Nrf2 at Serine-40 by protein kinase C was 
reported to trigger its nuclear translocation that is likely a critical signaling event leading to 
antioxidant response element (ARE)-mediated cellular antioxidant response (138). Nrf2 
forms a heterodimer with musculoaponeurotic fibrosarcoma oncogene homolog, thereby 
binding to ARE to regulate the basal and inducible expression of more than 200 genes 
including antioxidant genes (139). Classic Nrf2-target genes includes SOD, glutathione S-
transferase (GST), NAD(P)H: quinone oxidoreductase (NQO)1, NQO2, γ-GCS, glutamate 
cysteine ligase (GCL), GPx, TRX, TrxR, PRX, and heme oxygenase 1 (HO-1) (139). An 
important negative regulator of Nrf2 is a cytosolic protein Keap1. Under normal conditions, 
Keap1 binds with Nrf2 leading to its proteasomal degradation (140). ROS cause dissociation 
of Nrf2 from Keap1, leading to its translocation to the nucleus, which activates ARE, thus 
up-regulates a lot of ROS scavenging enzymes. 
Forkhead box class O (FoxO) family are also critical regulators of oxidative stress 
and exert this function at least partially by modulating the expression of several antioxidant 
enzymes (141). Oxidative stress activates FoxOs via phosphorylation by the Jun N-terminal 
kinase (JNK), which increases the expression of SOD2 and catalase (142).  
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ROS IN STEM CELLS 
ROS are known to play a role in affecting the fates of normal stem cells (143).  Stem 
cells were thought to maintain low levels of ROS. Elevated ROS has been observed to 
induce differentiation of embryonic stem cells into cardiovascular and mesendodermal cells 
(144, 145). NSCs and hematopoietic stem cells (HSCs) contain lower levels of ROS than 
their mature progeny, while increased ROS levels are associated with lowered self-renewal 
capacity, increased cell cycling and reduced viability (146-148). Studies of genetically 
manipulated mice have deepened the understanding of ROS effects on stem cells. Ataxia 
telangiectasia mutated gene deficient (Atm-/-) mice display increased levels of ROS, which 
lead to depletion of normal HSCs after serial transplantation (148). FoxOs are essential for 
the regulation of hematopoietic stem and progenitor cells. FoxO3a knockout mice showed 
elevated ROS that resulted in loss of HSC self-renewal capacity (149). PR 
domaincontaining16 (Prdm16) deficiency led to increased ROS levels and depletion of 
hematopoietic and neural stem cells (150). All these stem cell abnormalities can be restored 
or partially rescued by treatment with antioxidants (148-150).  
However, recent evidence suggests that appropriate levels of ROS are required to 
promote proliferation and survival of stem and progenitor cells. AKT1/2 double-deficient 
(AKT1-/-/AKT2-/-) HSC have been found to persist in the G0 phase of the cell cycle and 
demonstrate decreased ROS (151). Pharmacologically increasing ROS levels promotes the 
HSC proliferation and differentiation. Proliferative NSCs maintain a high ROS status and 
are highly responsive to ROS stimulation (152). ROS-mediated self-renewal and 
neurogenesis are dependent on PI3K/Akt pathway, and can be inhibited by NOX or PI3K 
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inhibitors. Taken together, ROS is tightly controlled in normal stem cell and keeping ROS at 
an appropriate level is crucial to maintaining stem cell functions. 
Redox status of cancer stem cell has not been well-characterized so far. Little is 
known about whether ROS regulate any signaling pathways in CSCs. CD24-/low/CD44+ 
breast cancer stem cells are enriched after radiation, perhaps due to lower levels of ROS in 
these cells (153). It has also been found that human and murine breast cancer stem cells 
contain lower cellular levels of ROS compared to the corresponding non-tumorigenic cells, 
which is likely related to their high ROS-scavenging capacity (46). Human gastrointestinal 
cancer stem-like cells with a high level of CD44 expression display an enhanced capacity 
for glutathione synthesis and defense against ROS, probably by stabilizing a glutathione 
substrate transporter xCT (154). CD44 ablation by siRNA depletes cellular glutathione and 
increases ROS in cancer cells (155). It has been shown salinomycin is effective in inhibiting 
prostate cancer cell including CSCs, which is probably due to the induction of ROS (156).  
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3. CANCER CELL METABOLISM 
Otto Warburg observed that, even in the presence of ample oxygen, cancer cells 
prefer to produce energy by a high rate of glycolysis followed by lactic acid fermentation, 
rather than by a comparatively low rate of glycolysis followed by oxidative phosphorylation 
like most normal cells, a phenomenon known as the “Warburg effect” (157). Although the 
Warburg effect has been generally accepted as a metabolic hallmark of cancer, its causal 
relationship with cancer progression remains unclear (158)  
Why do cancer cells that have a great need for ATP use such a low efficient way of 
metabolism? Warburg proposed that cancer cells have a permanent impairment of oxidative 
phosphorylation resulting in a compensatory increase of glycolysis to cope with a lack of 
ATP generation (159). While later studies have found that mitochondrial defects are rare and 
most tumor cells retain the capacity for oxidative metabolism (160, 161). The high 
glycolytic rate provides several advantages for proliferative cancer cells as long as glucose 
supplies are not limited. First, it produces ATP at a higher rate than oxidative 
phosphorylation and allows cells to use the most abundant extracellular nutrient, glucose 
(162). Although the yield of ATP per mol glucose consumed is low, when cancer cells are in 
resource competition with normal cells that produce ATP at a lower rate but a higher yield, 
they consume the resource more rapidly and have a growth advantage over normal 
cells(163).  Second, aerobic glycolysis allows cancer cells for ATP production in the 
absence of oxygen, which help the cancer cells proliferate in hypoxic conditions (164). 
Finally, aerobic glycolysis provides a biosynthetic advantage for cancer cells by producing 
intermediates for biosynthetic pathways including ribose sugars for nucleotides, glycerol and 
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citrate for lipids, nonessential amino acids and NADPH. So the Warburg effect benefits both 
bioenergetics and biosynthesis (162). 
Not only the tumor microenvironment but also oncogene activation can drive 
metabolic changes and lead to increased glucose consumption, decreased oxidative 
phosphorylation, and accompanying lactate production (158). Due to the high proliferation 
of cancer cells, hypoxia tends to be widespread in solid tumors. When cancer cells outgrow 
the recruited endothelial cells, new disorganized blood supplies usually form and further 
contribute to hypoxia. Therefore, the anaerobic use of glucose through glycolysis is required 
for cancer cells survival (165). Cells transformed by the oncogenes V-Src or H-Ras display 
increased expression of HIF-1 or VEGF and exhibit increased rates of aerobic glycolysis 
(165). Additionally, loss of tumor suppressor p53 prevents the synthesis of cytochrome c 
oxidase protein, which interferes with mitochondrial oxidative phosphorylation (158).  
The dependence of cancer cells on increased glucose uptake for aerobic glycolysis 
has been proven useful for tumor detection and monitoring.  [18F]fluorodeoxyglucose 
positron emission tomography (FDG–PET) imaging that uses a radioactive glucose analogue 
to detect regions of high glucose uptake has been widely applied in various tumor diagnosis 
and evaluation (162).  
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REGULATION OF CANCER CELL METABOLISM 
The PI3K/Akt/mTOR pathway is a master regulator of aerobic glycolysis in cancers. 
This pathway is activated by mutation in PI3K complex, mutations in tumor suppressor 
genes or by aberrant signaling from receptor tyrosine kinases (162). Akt stimulates 
glycolysis and increases lactate production in either nontransformed cells or cancer cells by 
increasing the expression and membrane translocation of glucose transporters and by 
phosphorylating key glycolytic enzymes, such as hexokinase and phosphofructokinase 2 
(166, 167). The activation of this pathway also stimulates protein and lipid synthesis and cell 
growth (160). 
A key transcription factor hypoxia-inducible factor-1 (HIF-1) regulates glucose 
metabolism under low oxygen conditions. Under normal oxygen conditions, HIF1 can be 
stabilized by oncogenic pathways including PI3K and mutations in tumor suppressors such 
as von Hippel–Lindau tumour suppressor (VHL), succinate dehydrogenase (SDH) and 
fumarate hydratase (FH) (162). HIF-1 activation increases the transcription of genes 
encoding glucose transporter and glycolytic enzymes (168). HIF-1 can also induce 
expression of pyruvate dehydrogenase kinase 1 (PDK1), which inhibits the mitochondrial 
pyruvate dehydrogenase (PDH) complex and reduce the entry of pyruvate into the 
tricarboxylic acid (TCA) cycle and increases conversion of pyruvate to lactate (169, 170). 
Another metabolic regulator of cancer cell is the oncogenic transcription factor c-
Myc. Overexpression of c-Myc collaborates with HIF-1 to promote glycolysis by induction 
of glucose transporter and glycolytic enzymes such as hexokinase 2 and PDK1 (171, 172). 
Additionally, c-Myc transformed cells require glutamine for survival and depriving these 
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cells of glutamine leads to a depletion of TCA cycle intermediates. c-Myc increases 
glutaminolysis which may thus generate more antioxidant glutathione for cancer cells (162). 
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TARGETING CANCER CELL METABOLISM 
Given that cancer cells depend on changes in metabolism to support their survival 
and growth, targeting cancer cells’ metabolism has become an important area of research. 
Although there have been attempts to block the glycolytic pathway in tumor cells using 
compounds such as 2-deoxyglucose (2-DG) and 3-bromopyruvate (3-BrPA), effective 
strategies have not been devised (173-175).  Several metabolic enzymes have been 
considered as candidate targets (Figure 5), and promising results have been obtained by 
using some compounds (176). Various compounds have been shown to block glucose uptake 
in cancer cells, but none of them are specific glucose transport inhibitors. Glucose 
transporter 1 (Glut1) and Glucose transporter 3 (Glut3) are expressed at much higher levels 
in cancer cells than in normal cells, suggesting that these transporters can be possible 
therapeutic targets. A competitive inhibitor of glucose, 2-deoxy-D-glucose (2-DG) is 
phosphorylated by hexokinase to produce 2-deoxyglucose-6-phosphate and competes with 
enzymes that metabolize glucose-6-phosphate (176). Cancer cells preferentially express 
hexokinase 2 (HK2) and repression of this enzyme is likely to be toxic to cancer cells. 3-
BrPA is an alkylating agent that has been shown to inhibit HK2 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), two key enzymes in the glycolytic pathway (173, 177). 
The derivative of 3-BrPA, 3-bromo-2-oxopropionate-1-propyl ester (3-BrOP), was 
developed by our laboratory. It has similar mechanisms of action as 3-BrPA and is 
chemically more stable, and has been shown to be highly potent in causing ATP depletion in 
cancer cells (178). Another glycolytic enzyme preferentially expressed by cancer cells is 
pyruvate kinase M2 (PKM2). Targeting PKM2 by inhibitors or shRNA can decrease cancer 
cell proliferation and tumorigenicity (179, 180). 
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Figure 5. Targeting metabolic enzymes in cancer. The metabolic enzymes that are 
considered as therapeutic targets for cancer (shown as red in the figure). GLS, 
glutaminase; GLUT, glucose transporter; IDH, isocitrate dehydrogenase; LDH, lactate 
dehydrogenase; PDK, pyruvate dehydrogenase kinase; PKM2, pyruvate kinase M2 
isoform. 
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HYPOTHEIS AND SPECIFIC AIMS 
Although cancer stem cells (CSCs) have been isolated from various types of cancer 
and their microenvironment is considered to be crucial for maintaining their stemness, the 
metabolic characteristics and mitochondrial function of cancer stem cells have not been well 
investigated. When cultured under serum-free conditions, CSCs can maintain their self-
renewal and multi-lineage differentiation abilities; while adding serum into the culture 
causes their differentiation.  It remains unknown how serum induces differentiation in CSCs 
and whether the metabolism differs between CSCs and other cancer cells. 
I hypothesize that GSCs have low mitochondrial activity and mainly depend on 
glycolysis for energy production compared with their differentiated progenies,  and that such 
metabolic properties can be utilized for designing new therapeutic strategies to eliminate 
GSCs. Specifically, the major goals of this study are to compare the mitochondrial 
respiratory function, glycolytic metabolism, and generation of reactive oxygen species in 
GSCs and in the downstream progeny cells induced by differentiation factors like FBS, to 
evaluate the role of glycolysis and ROS in GSCs survival and drug sensitivity, and to test 
new therapeutic strategies to effectively kill the drug-resistant GSCs. 
Considering the important role of CSCs in cancer development of disease recurrence, 
this proposed research project is of high significance in that it will provide new insights into 
cancer stem cell metabolism with potentially important therapeutic implications.   
The specific aims of my thesis project are to: 
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Specific Aim 1.  Evaluate the role of mitochondria and ROS in mediating GSC 
differentiation in response to serum induction.  
Specific Aim 2. Investigate the underlying mechanisms of how serum induces GSC 
differentiation. 
Specific Aim 3.  Design new therapeutic strategies to effectively kill GSCs based on 
their metabolic properties.   
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CHAPTER 2 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
32 
 
Cell Lines and Cell Culture 
GSC11, GSC23 and GBM3752 cell lines were isolated from three fresh surgical 
specimens of glioblastoma multiforme by Dr Howard Colman and Dr Xiao-nan Li’s groups. 
GSC11 and GSC23 were grown in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-
12 (DMEM/F12) medium (Mediatech Inc; Manassas, VA) supplemented with B27 
(Invitorgen; Carlsbad, CA), 20ng/ml epidermal growth factor (Miltenyi Biotec; Auburn, 
CA), 20ng/ml of basic fibroblast growth factor (Miltenyi Biotec; Auburn, CA) and 2 mM L-
glutamine (Mediatech Inc; Manassas, VA). GBM3752 cells came from orthotopic tumors in 
murine brain, as previously described (181) and were cultured in the same supplemented 
DMEM/F12 medium of GSC11 and GSC23 for less than 5 passages. Differentiation was 
induced with 5% FBS (Sigma-Aldrich; St. Louis, MO). For NAC treatment, cells were 
cultured under the 5% FBS containing medium with different concentrations of NAC 
(Sigma-Aldrich). The glioma cell line U87 and non-malignant human astrocytes (NHAs) 
were maintained in DMEM (Mediatech) supplemented with 10% FBS. Cells were cultured 
in a humidified incubator maintained at 37°C with 5% CO2 for 20 to 45 passages. Cells were 
treated with accutase (Sigma-Aldrich) before splitting or each treatment. The cells cultured 
under hypoxic conditions were maintained in a chamber with 2% O2. 
 
Chemicals and Reagents 
NAC, rotenone, antimycin, 4(2′-aminoethyl) amino-1,8-dimethylimidazo(1,2-a) 
quinoxaline (BMS-345541), carmustine (BCNU), temozolomide (TMZ), and 3-BrPA were 
purchased from Sigma-Aldrich. 3-BrOP was synthesized by esterification of 3-bromo-2-
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oxopropionate (Sigma-Aldrich) with 1-propanol (Sigma-Aldrich) under acidic conditions 
followed by neutralization with sodium carbonate and evaporation of the excess 1-propanol 
under a vacuum (178). 
 
RNA Isolation and RNA Microarray Analysis  
GSC11 cells were cultured in stem cell medium or differentiated medium for 1, 3, 
and 7 days in triplicate. Total RNA was extracted from 12 samples using the RNeasy Mini 
kit (QIAGEN Inc; Valencia, CA). Sample labeling was performed with an RNA 
amplification kit according to the manufacturer’s instructions (Applied Biosystems; Foster 
City, CA). We used 700 ng of total RNA for labeling and hybridization on HumanHT-12 v3 
expression beadchip (Illumina Inc; San Diego, CA) according to the manufacturer’s 
protocols (Illumina). After the bead chips were scanned with a BeadArray Reader (Illumina), 
the microarray data were normalized using the quantile normalization method in the Linear 
Models for Microarray Data (LIMMA) package in the R language (http://www.r-
project.org). The expression values of each gene were log2-transformed before further 
analysis. Primary microarray data are available in the National Center for Biotechnology 
Information Gene Expression Omnibus public database. BRB-ArrayTools were primarily 
used for statistical analysis of gene expression data (182). The t test was applied to identify 
the genes significantly different between two groups when compared. Cluster analysis was 
performed using the software programs Cluster and Heatmap was generated by Treeview 
(183). 
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Real-Time PCR Analysis 
The total RNA was reverse transcribed using a complementary DNA (cDNA) 
synthesis kit (Fermentas Inc; Glen Burnie, MD). The quantitative polymerase chain reaction 
analyses were carried out in a 25 µl reaction mixture that contained 1µl cDNA, 0.1µg 
oligonucleotide primer pairs, 12.5 µl SYBR Green Mix (Invitrogen) and 
diethylpyrocarbonate-treated water with the following primer sets (Table 2). 
 
Table 2. Human PCR primers for detecting levels of mRNA expression. 
Gene Forward Reverse 
SOX2 GCCTGGGCGCCGAGTGGA GGGCGAGCCGTTCATGTAGGTCTG 
Olig2 TGCGCAAGCTTTCCAAGA CAGCGAGTTGGTGAGCATGA 
CD133 CAGTCTGACCAGCGTGAAAA GGCCATCCAAATCTGTCCTA 
Notch1 GTGACTGCTCCCTCAACTTCAAT CTGTCACAGTGGCCGTCACT 
APH1B TTTCCGCGGTGGCCATGACT GAAGTGCTGGTTCCCTGAGG 
DLL1 CCTACTGCACAGAGCCGATCT ACAGCCTGGATAGCGGATACAC 
DTX3 TCCCTAAATGCCAGACTTGG GGACAGGACGAACGACATTT 
HES5 GCACCAGCCCAACTCCAAAC TGCAGGCACCACGAGTAGCC 
LFNG GATGACTGCACCATTGGCTACA GGCACCTGCTGCAGGTTCT 
MFNG GCGGTACCACTTGAACCTGT ATGTCTGTTCCCTGGTCCTG 
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Human Taqman probes were also used for detecting CD133, SOX2, Olig2 and 18S 
(Table 3). 
Table 3. Human Taqman primers for detecting levels of mRNA expression. Taqman 
primers from Applied Biosystems for the indicated genes and their sequence ID are provided. 
Primer Assay I.D. 
CD133 Hs01009250_m1 
SOX2 Hs01053049_s1 
Olig2 Hs00377820_m1 
18S Hs03928985_g1 
 
Flow Cytometric Analysis of CD133 
The cells were dissociated into single cells by using Accutase reagents (Sigma-
Aldrich) and were stained by allophycocyanin (APC)-conjugated CD133/1 clone AC133 
antibody (MACS Miltenyi Biotec, Cologne, Germany) or IgG2b-APC (MACS) according to 
the manufacturer’s instructions. 10µl propidium iodide (PI) was added before flow 
cytometry was performed. 
 
Immunocytochemistry 
Human neural stem cell functional identification kit (R&D Systems; Minneapolis, 
MN) was used for immunocytochemistry assay. Cells were grown on chamber slides coated 
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with laminin or in flasks and fixed with 10% formalin and permeablized with 0.3% Triton 
X-100 or fixed with -20°C 100% methanol. After blocked with 3% Goat 
serum+10%BSA/PBS for 30-60 minutes, cells were incubated with the primary antibodies 
diluted in 1%BSA/PBS over night and washed with PBS for 3 times. FITC conjugated goat 
anti-mouse IgG or Rhodamine red conjugated goat anti-mouse IgG were diluted in 
1%BSA/PBS and added onto the cells. The slides were washed with PBS for 3 times, 
stained with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) and observed under 
confocal microscope (Nikon). 
 
Immunoblotting 
Cultured cells were washed in PBS and homogenized in lysis buffer. Whole lysate 
was used and 20 µg protein was applied for each sample. Cell lysates were separated by 
electrophoresis on 10% or 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis 
and transferred to nitrocellulose membranes. After blocking with 5% non-fat milk/PBST for 
1 hour, the membranes were incubated overnight with primary antibodies at 4°C. Rabbit 
anti-human SOX2 (Cell Signaling Technology Inc; Danvers, MA), rabbit anti-human Olig2 
(Abcam; Cambridge, MA), mouse anti-human CD133 (MACS Miltenyi Biotec),  rabbit anti-
human Catalase (EMD Chemicals; Gibbstown, NJ), sheep anti-human SOD1 (EMD 
Chemicals), rabbit anti-human SOD2 (Santa Cruz Biotechnology Inc; Santa Cruz, CA), 
rabbit anti-human γ-GCSc (Santa Cruz), mouse anti-human phospho-IκBα (Cell Signaling; 
Danvers, MA ), mouse anti-human IκBα (Cell Signaling), rabbit anti-human phosphor-p65 
(Cell Signaling), rabbit anti-human p65 (Cell Signaling),  rabbit anti-human phosphor-H2AX 
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(EMD Millipore; Billerica, MA) rabbit anti-human H2AX (EMD Millipore) and mouse anti-
human β-actin (Sigma-Aldrich) were used as primary antibodies. The primary antibody was 
incubated at 4°C overnight and the secondary antibody was incubated for 1 hour at room 
temperature.The primary antibodies were detected with horseradish peroxidase-conjugated 
secondary antibodies. The membranes were developed using a Pierce Supersignal West Pico 
Chemiluminescent Substrate (Fisher Scientific Inc; Pittsburgh, PA). 
 
Measurement of Intracellular ROS 
Cells were plated in 6 well plates in stem cell medium or FBS-containing medium 
for 1, 3, or 7 days. Before performing the experiments, all samples were collected and 
dissociated into single cells by accutase. We washed cells with PBS once and resuspended 
them in prewarmed PBS containing freshly made solutions of 1µM CM-H2DCFDA or 5µM 
MitoSOX-Red (Molecular Probes; Eugene, OR) and incubate them at 37°C for 30 and 15 
minutes, respectively.  After loading, we spun the cells in PBS, washed them in PBS twice 
and performed the flow cytometric analysis. 
 
Glutathione Assay 
Measurement of total intracellular glutathione was performed by using a glutathione 
assay kit according to the manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI, 
USA). The GSC cells were cultured in serum-free for 7 days or cultured in 5% FBS-
containing medium for 1, 3 or 7 days. Subsequently, the cells were washed with PBS, 
harvested by centrifuging or by using a rubber policeman and were sonicated in cold MES 
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buffer.  A small portion of the supernatant was kept for the BCA protein assay (Pierce, 
Rockfold, IL). 1% 2-vinylpyridine solution was added to the residual supernatant for 
deproteinization and kept at -80°C till measurement.   
 
Oxygen Consumption Assay 
Samples were harvested and dissociated into singles cells by accutase, washed with 
PBS once and suspended in fresh 37°C medium pre-equilibrated with 21% oxygen at 4~10 
million cells/ml in stem cell medium. Oxygen consumption was measured in 1-ml medium 
in a sealed respiration chamber equipped with a thermostat control and microstirring device 
using an Oxytherm electrode unit (Hansatech Instruments Ltd; Norfolk, UK) at 37°C for 10 
to 20 minutes. Oxygen consumption by these cells in the chamber was measured and 
constantly monitored at 37°C using a Clark-type oxygen electrode (Hansatech Instruments). 
The oxygen consumption was expressed in nanomoles of O2 consumed as a function of time 
(nmol/ml/minute). 
 
Cell Viability Assay 
Cell-growth inhibition was assayed using a colorimetric assay with MTS (Promega). 
Briefly, GSCs were seeded in 96-well plates and then treated with indicated compounds at 
various concentrations. After 72 hours of incubation, 40 µl of the MTS solution was added 
to each well and then incubated for another 4 hours. The absorbance in each well at 490 nm 
was measured using a Multiskan plate reader (Thermo Scientific). Cell apoptosis and 
necrosis were measured using flow cytometric analysis of cells double-stained with FITC-
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annexin-V and propidium iodide. Briefly, samples were collected, dissociated, washed with 
cold PBS, and suspended in the annexin-V binding buffer, and then stained with annexin-V 
for 15 minutes at room temperature, washed, and stained with PI. The samples were 
analyzed using a FACSCalibur flow cytometer equipped with the CellQuest Pro software 
program (Becton-Dickinson). 
 
Tumor Sphere Forming Assay 
GSCs were treated with indicated compounds for 3 hours and then seeded in fresh 
medium in 96-well plates at cell numbers from 10 to 1000 cells per well and incubated at 
37°C under normoxia condition; neurospheres were counted under a microscope (Nikon) 
after 3 weeks of incubations. 
 
Glucose Uptake Assay 
GSCs were induced by 10% FBS for 20 days and then compared with the control 
GSCs. Briefly, the medium in the cell culture were replaced with the glucose-free medium 
and incubated for 2 hours at 37°C, and then incubated with [3H]-2-deoxyglucose (0.4 µCi/ml) 
for another hour. After washing with cold PBS, each sample was suspended in 0.5 ml of 
water and transferred to a vial with 3 ml of scintillation fluid. The radioactivity of the 
samples was detected using a liquid scintillation machine (Beckman Coulter).  
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Lactate Production Assay 
To measure the lactate production by GSCs in long-term culture, GSCs were plated 
in six-well plates with the fresh medium for indicated times. Aliquots of the culture medium 
were analysed by an Accutrend lactate analyzer (Roche). To measure the lactate production 
in short-term culture, cells were plated in 96-well plates and treated with indicated 
compounds for 3 hours. A colorimetric lactate assay kit was used according to the 
manufacturer’s protocol (Eton Bioscience). Absorbance in each well at 490 nm was 
measured using a Multiskan plate reader. 
 
ATP Depletion Assay 
GSCs were plated in 96-well plates and then treated with indicated compounds for 3 
or 6 hours, 100 µl of mixed CellTiter-Glo luminescent reagent (Promega) was added to each 
well and incubated for 10 minutes on an orbital shaker. Luminescence in each well was 
measured using a Fluoroskan luminescence scanner (Thermo Scientific). 
 
Single-Cell Gel Electrophoresis Assay (Comet Assay) 
After GSCs were treated with indicated compounds for 3 hours, cell suspensions 
mixed with 0.5% low-melting-point agar was placed onto a 24 × 50-mm slide precoated 
with 1% normal-melting-point agar. After agar distribution and solidification, slides were 
soaked in a prechilled fresh lysing solution (2.5 µM NaCl, 100 mM 
ethylenediaminetetraacetic acid, 10 mM Tris-HCl, 1% Triton X-100, pH 10) for 1 hour at 
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4°C. After rinsing with 0.4 M Tris buffer (pH 7.5), slides were placed in a reservoir filled 
with fresh electrophoresis buffer (300 mM NaOH, 1 mM ethylenediaminetetraacetic acid, 
pH >13) for 15 minutes and electrophoresed for another 15 minutes (25 V, 300 mA). Slides 
were then stained with CYBR Green I (Trevigen) and photographed under a fluorescent 
microscope (Nikon). The tail DNA percentage, which indicates damaged DNA, was 
analyzed using the Casp software program (version 1.2.2) provided by the CASPLab Comet 
Assay Project.  
 
GAPDH Enzymatic Activity Assay 
Purified GAPDH enzyme from rabbit muscle (Sigma-Aldrich) or protein extracts 
prepared from GSC11 cells were used in the GAPDH assays in vitro, using GAPDH Assay 
Kit (ScienCell) according to the manufacturer’s protocol. Purified GAPDH was incubated in 
vitro with the indicated compounds (BCNU and 3-BrOP) for 30 minutes, then added to a 
mixture of 6.67 mM 3-phosphoglyceric acid, 3.33 mM L-cysteine, 117 µM β-NADH, 1.13 
mM ATP, 3.33 U/ml 3-phosphoglycerate kinase, and 100 mM triethanolamine buffer (pH 
7.6), and change in NADH fluorescence was then monitored using a Fluoroskan 
spectrometer every minute for up to 20 minutes. For analysis of GAPDH activity in cell 
extracts, GSC11 cells were first incubated with or without 3-BrOP, BCNU, or their 
combination for 30 min, and protein lysates were prepared and immediately used for 
GAPDH activity assay without addition of 3-BrOP or BCNU in vitro. 
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Tumorigenicity in Subcutaneous Mouse Xenografts 
GSC11 cells cultured under neural sphere culture conditions (GSC medium) as 
mentioned above were divided into 4 groups. One group continued to be cultured in the 
GSC medium, another group was cultured in GSC medium supplemented with 5%FBS, the 
third group was cultured in GSC medium in the presence of 20mM NAC and the last group 
was cultured in GSC medium with 5% FBS and 20mM NAC. After 7 days, cells were 
collected, treated with accutase into single cells and inoculated into the right flank of nude 
mice at 2×106 cells/mouse. The mice were euthanized when the tumor diameter was greater 
than 20 mm. 
 
3-BrOP and BCNU Treatment 
GSC11 cells were cultured in GSC medium and made into single cells by accutase. 
The same amount of GSC11 cells were exposed to PBS, 20µM BCNU, 20µM 3-BrOP or 
20µM BCNU and 20µM 3-BrOP in GSC medium and cultured at 37°C. After 6 hours, cells 
were collected, washed and inoculated into SCID mice brain at 2×105 cells/mouse. The 
mice were euthanized when they developed signs of neurological deficit or became 
moribund. 
 
Statistical Analysis 
Data were analyzed using GraphPad Prism 5 (GraphPad Software). Data graphed 
with error bars represent mean and SEM from experiments done in triplicate unless 
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otherwise noted. A two-sided Student’s t test was used to determine the significance of any 
differences. Survival curves were compared between different groups by Logrank Test. 
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CHAPTER 3 
Mitochondrial function and ROS increase in serum-induced 
GSC differentiation 
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Establishment of GSC culture and induction of aberrant differentiation by serum  
We used three human glioblastoma stem cell lines (GSC11, GSC23, and GBM3752) 
in this study. GSC11 and GSC23 were originally derived from fresh surgical specimens of 
adult glioblastoma multiforme and maintained in serum-free neural sphere culture medium 
(184, 185).  GBM3752 cells were derived from fresh surgical specimen of glioblastoma 
multiforme, inoculated into SCID mice’s brain and passed in SCID mice as orthotopic brain 
tumors (181). GBM3752 cells were prepared freshly for in vitro study in serum-free medium 
during the first several passages. These cells all grew in serum free stem cell medium 
(DMEM/F-12 medium) containing EGF and bFGF, and exhibited the morphology of stem-
like neurospheres (Figure 6). The presence of serum (5% FBS) in culture medium caused a 
significant change in cell morphology, manifested by a loss of neurosphere formation and 
the appearance of differentiated cells attaching to the culture dishes (Figure 6). 
About 50%-60% of GSC11 and GSC23 cultured under serum free medium were 
CD133-positive cells (Figure 7A). Adding FBS into the culture medium caused a substantial 
decrease of CD133 expression in a time-dependent manner (Figure 7A-B). After 3 days 
cultured in serum-containing medium, the percentage of CD133+ cells dropped to 30-45% in 
GSC11 cells, which was significantly decreased compared to the cells cultured in serum-free 
medium. After 7 days cultured in serum-containing medium, the percentage of CD133+ 
GSC11 cells further dropped to around 20%. The decrease of CD133 expression was 
confirmed by western blot (Figure 7C). The similar time-dependent decrease of CD133+ was 
also observed in GSC23 cells (Figure 7D-E). 
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Figure 6. Serum induces GSCs aberrant differentiation. Glioblastoma stem cells 
(GSC11 and GBM3752) formed neurospheres in the serum-free medium 
supplemented with EGF and bFGF. Exposure of the cells to serum (5% FBS) for 3 
days led to a loss of neurosphere formation in both cell lines. 
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Figure 7. Serum causes CD133 decrease. (A) Flow cytometric analysis of CD133 
expression in GSC11 cells before and after exposure to serum for 7 days. (B) 
Quantitation of the percentage of CD133+ cells before and after GSC11 cells 
exposed to serum for 1, 3, and 7 days. *, P<0.05. (C) Western blot analysis of 
CD133 expression in GSC11 cells before and after exposure to serum for 1, 3, and 7 
days as indicated. (D) Flow cytometric analysis of CD133 expression in GSC23 
cells before and after exposure to serum for 7 days. (E) Quantitation of the 
percentage of CD133+ cells before and after GSC23 cells were exposed to serum for 
1, 3, and 7 days.  *, P<0.05.  
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Quantitative RT-PCR and western blot analyses of GSC11 cells revealed a 
significant decrease in mRNA expression of SOX2 and Olig2, two transcription factors that 
are important for neural stem cells and neural progenitor cells, in serum-induced cells 
(Figure 8A). The mRNA expression of Notch1, a molecule important for promoting neural 
stem cell function(186), was also significantly down regulated in serum-induced cells 
(Figure 8A). The downregulation of SOX2 and Olig2 was also detected on protein levels by 
western blot (Figure 8B). In contrast, the expression of a differentiation marker ANXA1 was 
significantly increased after exposure of GSC11 cells to serum (Figure 8B). Similar results 
were obtained from GSC23 cells (Figure 8C-D). 
High expression levels of a neural stem cell marker Nestin was detected in GSC 
spheres by immunocytochemistry (Figure 9). The exposure to FBS did not cause obvious 
change in Nestin expression. Glial fibrillary acidic protein (GFAP), a marker which is often 
detected in astrocytes, was also detected in GSC spheres by immunocytochemistry (Figure 
10). Serum exposure did not cause substantial change of GFAP expression. Low level 
expression of a neuron marker β-III tubulin and an oligodendrocyte marker O4 was detected 
in GSC cells and serum induction caused an upregulation of both proteins (Figure 11).  
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Figure 8. Serum causes decreases of SOX2, Olig2 and Notch1 and an increase of 
ANXA1. (A) Expression of SOX2, Olig2, and Notch1 mRNA in GSC11 cells before 
and after exposure to serum for 3 days. Expression of mRNA was measured by 
quantitative real-time PCR.  **, P<0.001 *, P<0.05. (B) Effect of serum exposure on 
protein expression of stem cell markers SOX2 and Olig2 and differentiation marker 
ANXA1. GSC11 cells were exposed to 5% FBS for 1, 3, and 7 days (D1, D3, D7). 
SOX2, Olig2, ANXA1 were detected by western blot analysis. (C) Expression of 
SOX2, Olig2, and Notch1 mRNA in GSC23 cells before and after exposure to serum 
for 3 days. Expression of mRNA was measured by quantitative real-time PCR.  **, 
P<0.001 *, P<0.05.  (D) Effect of serum exposure on protein expression of stem cell 
markers SOX2 and Olig2 and differentiation marker ANXA1. GSC23 cells were 
exposed to 5% FBS for 1, 3, and 7 days (D1, D3, D7) as indicated, and cellular 
proteins were analyzed for expression of SOX2, Olig2 and ANXA1 by western 
blotting.    
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Figure 9. GSCs express Nestin. (A) Expression of Nestin (green) in GSC11 
neurospheres was detected by immunocytochemistry staining. Counterstaining of 
the nuclei with DAPI is depicted (blue). (B) Immunocytochemistry staining of 
Nestin (green) and DAPI (blue) in GSC11 cells cultured in GSC medium or 
exposed to 5% FBS for 7 days. 
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Figure 10. GSCs express GFAP. (A) Expression of GFAP (green) in GSC11 
neurospheres by Immunocytochemistry staining. Counterstaining of the nuclei with 
DAPI is depicted (blue). (B) Immunocytochemistry staining of GFAP (green) and 
DAPI (blue) in GSC11 cells cultured in GSC medium or exposed to 5% FBS for 7 
days. 
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Figure 11. Expression of β-III tubulin and O4 increases in serum-induced GSC11 
cells. (A) Immunocytochemistry staining of β-III tubulin (red) and DAPI (blue) in 
GSC11 cells cultured in GSC medium or exposed to 5% FBS for 7 days. (B) 
Immunocytochemistry staining of O4 (red) and DAPI (blue) in GSC11 cells cultured 
in GSC medium or exposed to 5% FBS for 7 days. 
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FBS causes gene expression change in aberrant differentiated cells 
To investigate the molecular events and potential alterations of signaling pathways in 
response to serum-induced differentiation in the glioblastoma stem cells, we treated GSC11 
cells with 5% FBS for 1, 3, and 7 days in triplicate cultures, and isolated RNA from each 
sample for determination of gene expression profiles. As shown in Figure 12A, clustering 
analysis of the gene expression data from microarray analysis revealed that the serum-
treated GSC11 cells exhibited gene expression profiles distinct from that of the GSC11 cells 
cultured in serum-free medium.  There was a further shift of gene expression profiles as the 
time of serum exposure prolonged. The fact that three separate samples of the same time 
point (biological triplicates) displayed similar gene expression patterns and clustered in the 
same group reflects the high reproducibility of this experimental system. Using the 
Ingenuity Pathway Analysis software, we compared the gene expression between GSCs and 
aberrant differentiated cells and we found that the Nrf2 mediated oxidative stress response 
pathway was the most significant alteration (p = 0.00045) in cells cultured under serum 
condition for 1 day.  On the first day of initiating differentiation, the molecules related to 
Nrf2 mediated oxidative stress response pathway were significantly altered (Figure 12B). 
Table 4 shows the genes involved in oxidative stress response identified by this analysis in 
GSC11 cells. Among the genes identified, SOD2, catalase, NQO1, peroxiredoxin 1, 
thioredoxin reductase 1, and glutamate-cysteine ligase are involved in ROS scavenging. 
These results suggest that serum-induced differentiation of GSCs was likely associated with 
oxidative stress.  
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Figure 12. The gene expression changes in aberrant differentiated cells.  (A) 
Overall gene expression pattern of GSC11 cells. GSC11 cells maintained in serum-
free stem cell medium were exposed to 5% FBS for 1, 3, and 7 days (each time 
point had triplicate culture flasks A-C). After variance filtering, a total of 7613 
probes were used for unsupervised hierarchical clustering with the similarity metric 
of uncentered correlation. The red and green colors represent high and low 
expression, respectively, as indicated in the log2-transformed scale bar. (B) 
Expression pattern of genes associated with the Nrf2-mediated oxidative stress 
response pathway. Genes with expression showing significant difference between 
control and 1 day in serum-free condition in GSC11 cells were selected by two-
sample t-test (P < 0.001). Expression values of each gene in 1, 3 and 7 days were 
normalized by its mean value of controls, and visualized.  
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Table 4. The significantly changed genes in the Nrf2-mediated oxidative stress response 
pathway.  
Gene p value(Day1 vs Control) Fold change (Day1 vs Control) 
GSTM1 0.0008 -3.18 
GSTM2 4.3E-05 -3.44 
CAT 0.00078 -1.83 
GSTT1 0.00028 -2.49 
GSTM1 0.00043 -2.06 
JUND 0.00068 -1.65 
GSTM2 0.00057 -2.82 
PIK3R2 0.0002 -1.89 
PRKCZ 0.00011 -1.76 
MAF 0.0008 -2.02 
MAP3K1 0.00091 -1.78 
PIK3R1 0.00029 -2.63 
SCARB1 6.1E-05 -2.39 
JUNB 6.7E-05 2.53 
MAFG 0.00044 1.76 
GCLM 6.8E-05 2.26 
TXNRD1 2.7E-05 1.60 
HMOX1 0.00017 3.06 
JUN 7.5E-05 2.37 
NQO1 0.00042 2.22 
SOD2 0.00051 1.78 
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MAP2K3 0.00061 1.71 
PRDX1 0.00029 1.30 
NSMAF 0.00063 1.41 
ACTG1 0.00057 1.17 
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Serum induces increase of mitochondrial superoxide  
The observations that exposure of GSCs to serum caused a consistent oxidative 
stress response prompted us to test possible changes in cellular redox status. Since 
mitochondria are the major sites of ROS production, we used MitoSox Red to detect 
mitochondrial superoxide (O2-) and 5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein 
diacetate acetyl ester (DCF-DA) to measure total cellular H2O2 and other ROS. We found 
that serum induced a substantial increase of mitochondrial O2- in a time-dependent manner, 
with an increase of median value from 46 units in control cells (without serum) to 67, 188, 
and 268 units on day 1, day 3, and day 7 after serum exposure, respectively (Figure 13A).  
Total cellular H2O2 and other ROS as measured by DCF-DA also showed an increase, from 
84 units in the control to 112, 126, and 159 units on day 1, day 3, and day 7, respectively 
(Figure 13B).  Similar results were also observed in GSC23 (Figure 13C-D) and GBM3752 
(Figure 13E-F), suggesting that the induction of mitochondrial O2- generation might be an 
important early event in serum-induced differentiation of GSCs. 
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Figure 13. Effect of serum on mitochondrial superoxide and cellular ROS. 
Mitochondrial superoxide was measured by flow cytometric analysis after cells 
were stained with MitoSOX-Red. Cellular ROS were detected using CM-H2-
DCFDA staining followed by flow cytometric analysis. The numbers in 
parentheses indicate the median fluorescent intensity. (A) Increase of mitochondrial 
superoxide in GSC11 cells after exposure to 5% FBS for 1, 3, and 7 days (D1, D3, 
D7). (B) Analysis of total cellular H2O2 and other ROS in GSC11 cells before and 
after exposure to serum. (C) Increase of mitochondrial superoxide in GSC23 cells 
after exposure to 5% FBS for 1, 3, and 7 days. (D) Analysis of total cellular H2O2 
and other ROS in GSC23 cells before and after exposure to serum for 3 and 7 days. 
(E) Increase of mitochondrial superoxide in GBM3752 cells after exposure to 5% 
FBS for 3 days (D3). (F) Analysis of total cellular H2O2 and other ROS in 
GBM3752 cells before and after exposure to serum for 3 days.  
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We then tested if the alterations in mitochondrial O2- and cellular ROS might cause 
stress response and upregulation of antioxidant enzymes. As shown in Figure 14, there was a 
time-dependent increase in expression of SOD2, a mitochondrial superoxide dismutase that 
converts O2- to H2O2. Interestingly, the cytosolic superoxide dismutase (SOD1) did not 
exhibit any significant change after serum exposure (Figure 14A). The expression of 
catalase, an enzyme that converts cellular H2O2 to water and oxygen, increased after serum 
incubation (Figure 14A). Similar results were obtained from GSC23 (Figure 14B). These 
data together suggest that the increased expression of SOD2 might be a specific stress 
response to elevated mitochondrial O2- generation induced by serum. SOD2 converted O2- to 
H2O2, which was then able to pass the mitochondrial membranes and further converted to O2 
and H2O by catalase, resulting in a moderate overall increase of total cellular ROS detected 
by DCF-DA. 
 
 
 
Figure 14. Effect of serum on expression of SOD1, SOD2 and catalase. (A) 
Western blot analysis of SOD1, SOD2, and catalase in GSC11 cells before and after 
exposure to serum for 1, 3 and 7 days (D1, D3, D7). (B) Western blot analysis of 
SOD1, SOD2, and catalase in GSC23 cells before and after exposure to serum for 1, 
3 and 7 days (D1, D3, D7). 
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Total glutathione (GSH), the major endogenous antioxidant, became deficient in a 
time-dependent manner in the GSC11 aberrant differentiated cells (Figure 15A).  For 
GSC23 cells induced by serum, total GSH increased on day 1 and decreased subsequently 
on day 3 and day 7 (Figure 15B). A rate limiting enzyme in GSH biosynthesis, γ-
glutamylcysteine synthetase heavy subunit (γ-GCSc), increased in aberrant differentiated 
GSC11 on day 7 (Figure 15C). These results suggested that serum induction caused 
oxidative stress that led to an upregulation of GSH synthesis enzyme. But this stress 
response failed to provide sufficient GSH for the cells to scavenge the oxidative stress. 
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Figure 15. Serum induction causes glutathione depletion. (A)Total GSH/protein 
ratio in GSC11 cells before and after exposure to serum for 1, 3 and 7 days. (B) Total 
GSH/protein ratio in GSC23 cells before and after exposure to serum for 1, 3 and 7 
days. (C) WB blot detection of γ-GCSc expression in GSC11 cells before and after 
exposure to serum for 1, 3 and 7 days. 
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Activation of mitochondrial respiration by serum in glioblastoma stem cells  
Since mitochondrial superoxide is mainly generated during respiration due to a 
release of electrons from complexes I and III of the electron transport chain, we speculated 
that the increased mitochondrial O2- might be a result of active mitochondrial respiration 
induced by serum, and not a consequence of a slower superoxide elimination since SOD2 
expression was increased. To test this possibility, we measured oxygen consumption by 
GSCs as an indicator of mitochondrial respiration. As shown in Figure 16A-B, exposure of 
GSC11 cells to serum led to a time-dependent significant increase of oxygen consumption, 
with approximately 100% increase by day 3. The increase in mitochondrial respiration was 
also consistently observed in GSC23 (Figure 16C) and GBM3752 cells (Figure 16D). 
Since the oxygen consumption increase in aberrant differentiated cells might be due 
to mitochondria quantity increase or mitochondrial function increase, we further measured 
the mitochondria quantity by using a fluorescent dye, MitoTracker Green. Flow cytometric 
analysis showed that serum did not cause any significant change in mitochondrial mass 
(Figure 17A), suggesting that the increased respiration was mainly a functional activation of 
mitochondria instead of an increase of mitochondria biogenesis. Similarly, no significant 
changes in mitochondrial mass were observed in GSC23 (Figure 17B) and GBM3752 cells 
(Figure 17C).   
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Figure 16. Increase of mitochondrial respiration in aberrant differentiated cells. 
(A) Comparison of oxygen consumption in GSC11 cells before and after exposure to 
serum for 1, 3 and 7 days. Oxygen consumption was measured using an Oxytherm 
system as described in Methods. (B) Quantitative analysis of oxygen consumption in 
GSC11 cells exposed to serum for 1, 3, and 7 days. *, P<0.01. (C) Quantitative 
analysis of oxygen consumption in GSC23 cells exposed to serum for 3 days. *, 
P<0.01. (D) Comparison of oxygen consumption in GBM3752 cells before and after 
exposure to serum for 3 days. 
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 Figure 17. Serum does not induce mitochondria biogenesis. Mitochondrial mass 
was measured by MitoTracker-Green. No change in mitochondrial mass was found in 
GSC11 (A), GSC23 (B) and GBM3752 (C) cells after exposed to serum for 1 day 
(D1), 3 days (D3), or 7days (D7). The numbers in parentheses indicate the median 
fluorescent values. 
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CHAPTER 4 
ROS mediate GSC differentiation in response to serum 
induction 
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Oxidative respiration inhibitor CCCP does not inhibit serum-induced aberrant 
differentiation. 
The effect of carbonyl cyanide m-chloro phenyl hydrazone (CCCP), a mitochondrial 
uncoupling agent that causes an uncoupling of the proton gradient and reduces ATP 
synthesis, on aberrant differentiation was tested. Different dosages of CCCP were used to 
treat the GSC11 cells, which showed that 5µM of CCCP didn’t cause much cell death (data 
not shown). Therefore, 2µM and 5µM of CCCP were used to test its effects on inhibiting the 
stem cell related gene expression change. 5 µM of CCCP prevented the decrease of CD133 
induced by serum in GSC11 cells (Figure 18A), but no inhibition of SOX2 and Olig2 
mRNA decreases was found by real-time PCR (Figure 18A). CCCP either didn’t inhibit the 
decrease of SOX2 and increase of ANXA1 caused by serum on protein levels (Figure 18B). 
We measured the mitochondrial superoxide change in the GSC11 cells treated by CCCP. 
The results showed that CCCP did not inhibit the mitochondrial superoxide increase in 
aberrant differentiated cells (Figure 19).  
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Figure 18. Effects of mitochondrial uncoupler CCCP on the expression of SOX2, 
Olig2, CD133 and ANXA1. (A) mRNA expression of SOX2, Olig2 and CD133 in 
GSC11 cells, as measured by quantitative RT-PCR. GSC11 were exposed to serum 
(5% FBS) for 3 days in the presence and absence of 2µM or 5µM CCCP. *, p<0.05. 
(B) mRNA expression of SOX2, Olig2 and CD133 in GSC23 cells, as measured by 
quantitative RT-PCR. GSC23 were exposed to serum (5% FBS) for 3 days in the 
presence and absence of 2µM or 5µM CCCP. *, p<0.05. (C) Protein levels of SOX2, 
Olig2 and CD133 in GSC11 and GSC23 cells, as measured by western blot. GSC11 
and GSC23 cells were cultured with or without presence of serum (5% FBS) for 3 
days in the presence and absence of 2µM or 5µM CCCP. 
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Figure 19. CCCP can’t inhibit mitochondrial superoxide increase. 
Mitochondrial superoxide was measured by flow cytometric analysis after cells 
were stained with MitoSOX-Red. GSC11 cells were cultured in GSC medium 
or FBS-containing medium with or without the presence of 2µM or 5µM of 
CCCP for 1 day. 
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Compounds increasing mitochondrial superoxide cause CD133 decrease 
            In order to test whether the activation of mitochondrial function would affect serum 
induced aberrant differentiation, several mitochondrial electron transport chain inhibitors 
were used to disrupt mitochondrial function. Mitochondria ETC complex I inhibitor 
rotenone and complex III inhibitor antimycin were added with serum to the GSCs. Both 
ETC inhibitors caused an increase of mitochondrial superoxide (Figure 20). Neither of them 
prevented the GSCs from attaching to the flasks and showing differentiated morphology 
(Figure 21A). Adding rotenone or antimycin even caused further decreases of CD133 on 
both mRNA and protein levels (Figure 21B-C). 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Mitochondrial electron transport chain inhibitors antimycin and 
rotenone cause increase of mitochondrial superoxide. Mitochondrial superoxide 
was measured by flow cytometric analysis after cells were stained with MitoSOX-
Red. GSC23 cells were cultured in GSC medium or FBS-containing medium with 
2µM antimycin or 1µM rotenone.  
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Figure 21. Antimycin and rotenone cause further decrease of CD133 in serum-
induced cells. (A) GSC11 cells were cultured in GSC medium or FBS-containing 
medium with 2µM antimycin or 1µM rotenone. (B) mRNA levels of CD133 were 
measured by real-time PCR after GSC23 cells were cultured in GSC medium or FBS-
containing medium with 2µM antimycin or 1µM rotenone.  (C) GSC23 cells were 
cultured in GSC medium or FBS-containing medium with or without the presence of 
2µM antimycin or 1µM rotenone.  Protein levels of CD133 were measured by western 
blot. 
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H2O2 causes the stem cell markers gene expression decrease  
Exposure of GSCs to serum caused an increase in mitochondrial respiration and O2- 
generation. However, neither the mitochondria ETC inhibitors (rotenone and antimycin) nor 
the oxidative phosphorylation inhibitor (CCCP) prevented the stem cell markers decrease or 
differentiation marker increase. Rotenone and antimycin caused further increase of 
mitochondrial superoxide and induced further CD133 decreases. Therefore, it seems 
mitochondrial ROS instead of the activation of mitochondria itself plays an important role in 
aberrant differentiation. I further tested the potential role of ROS increase in serum-induced 
differentiation by using hydrogen peroxide. H2O2 caused a similar increase of mitochondrial 
ROS as serum did in GSC11 and GSC23 cells (Figure 22A-B). The short-term treatment of 
H2O2 led to significant decreases of SOX2, Olig2 and CD133 mRNA expression in GSC11 
cells (Figure 22C). Similarly, the short-term treatment of H2O2 caused significant decreases 
of SOX2 and CD133 mRNA expression in GSC23 cells (Figure 22D). 
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Figure 22. Hydrogen peroxide causes mitochondrial superoxide increase and 
decreases of Olig2, SOX2 and CD133. (A) Mitochondrial superoxide was measured 
by flow cytometric analysis before or after GSC11 cells were treated with 200µM or 
1mM of H2O2 for 1 hour. (B) Mitochondrial superoxide was measured by flow 
cytometric analysis before or after GSC23 cells were treated with 500µM or 1mM of 
H2O2 for 1 hour. (C) mRNA expression of SOX2, Olig2 and CD133 in GSC11 cells, as 
measured by quantitative RT-PCR. GSC11 were treated with 200µM or 1mM H2O2 for 
6 times with 1 hour intervals. *, p<0.05. (D) mRNA expression of SOX2, Olig2 and 
CD133 in GSC23 cells, as measured by quantitative RT-PCR. GSC23 were treated 
with 500µM or for 6 times with 1 hour intervals. *, p<0.05. 
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Antioxidant NAC prevents the serum-induced differentiation 
 N-Acetyl-Cysteine (NAC), a precursor for glutathione synthesis with potent 
antioxidant property capable of reducing various types of ROS stress, was used to prevent 
the increase of mitochondrial O2- in serum-treated GSCs.  As shown in Figure 23A, 
incubation of GSC11 cells with serum for 7 days caused a significant increase of 
mitochondrial O2-, and 20µM of NAC effectively suppressed such ROS increase. Similar 
results were obtained from GSC23 cells (Figure 23B).  
 
 
 
 
 
 
Figure 23. NAC suppresses serum-induced mitochondrial superoxide 
increase. Mitochondrial superoxide was detected by flow cytometry after cells 
were stained with MitoSox-Red. (A) GSC11 cells were cultured in serum-
containing medium with or without the presence of 20mM NAC for 7 days. (B) 
GSC23 cells were cultured in serum-containing medium with or without the 
presence of 20mM NAC for 7 days. 
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Importantly, NAC was able to prevent serum-induced differentiation and keep the 
GSC11 cells in stem-like neurospheres (Figure 24A), and to preserve the expression of 
CD133 in GSC11 cells (Figure 24B), suggesting that the increase in mitochondrial 
superoxide might play an important role in mediating serum-induced GSC differentiation.   
 
 
 
 
Figure 24. NAC prevents serum-induced aberrant differentiation. (A) 
Comparison of neurosphere formation in GSC11 cells cultured in serum-containing 
medium in the presence and absence of 20 mM NAC for 7 days. (B) NAC 
suppressed serum-induced loss of CD133 expression. GSC23 cells were exposed to 
serum for 1, 3, or 7 days in the presence or absence of 20 mM NAC as indicated, 
and CD133-possitive cells were measured by flow cytometric analysis.*, P<0.05. 
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Since there was a significant decrease in expression of SOX2, Olig2, and Notch1 
during serum-induced differentiation, we tested if NAC could suppress serum-induced 
differentiation by preventing the down-regulation of these molecules important for stem cell 
maintenance. As shown in Figure 25A, quantitative RT-PCR revealed that addition of NAC 
to the serum-treated GSC11 cells largely prevented the decrease of SOX2 and Olig2 
expression, suggesting that the expression of these two molecules might be redox-sensitive.  
Similar results were also observed in another glioblastoma stem line GSC23 (Figure 25B).  
Furthermore, gene expression analysis of molecules involved in the Notch pathway revealed 
that serum caused a significant decrease in the expression of Notch1, MFNG, LFNG, HES5, 
DTX3, and DLL1 in GSC11 cells (Figure 25C).  The presence of antioxidant NAC largely 
prevented the down regulation of the Notch-related genes (Figure 25C), suggesting that 
cellular redox status might play a major role in Notch signaling. 
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Figure 25. Effect of antioxidant NAC on the expression of SOX2, Olig2 and 
Notch pathway. Antioxidant NAC suppressed serum-induced down regulation of 
SOX2 and Olig2 mRNA expression in GSCs, as measured by quantitative real-time 
PCR. GSC11 (A) and GSC23 (B) were exposed to serum (5% FBS) for 3 days in the 
presence and absence of 20 mM NAC. The expression of SOX2 and Olig2 
messenger RNA in each sample was measured by quantitative RT-PCR. (C) 
Antioxidant NAC suppressed serum-induced down regulation of the notch pathway. 
GSC11 cells were incubated with serum (5%FBS) for 3 days in the presence or 
absence of 20 mM NAC.  RNA was isolated from each sample and the expression of 
molecules involved in notch signaling was measured by quantitative real-time PCR.   
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Serum induction activates NFĸB pathway  
ROS seems to play an important role in mediating serum-induced differentiation. In 
order to clarify the possible mechanism of how mitochondrial ROS change causes the GSC 
differentiation, we analyzed the data of microarray and searched for significantly altered 
gene expressions in aberrant differentiated cells. A ROS regulating signaling, NFĸB 
pathway seems to be a possible candidate. Its downstream targets CD44, IL8, IL11, Cyclin 
D1, TFP12 and PLAUR were significantly up-regulated in the aberrant differentiated cells 
(Table 5). We assayed the NFĸB pathway by western blot and found phosphorylated IĸBα 
and phosphorylated p65 were increased in serum-induced aberrant differentiated cells on 
day three in both GSC11 and GSC23, indicating the activation of NFĸB pathway after serum 
induction (Figure 26).  
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Table 5. NFĸB pathway downstream targets expression in the microarray analysis. The 
mRNA expression signal of GSC11 cells cultured in serum-free medium and 5%FBS-
containing medium for 1, 3 and 7 days. P value was calculated by t-test based on the mRNA 
expression values. CD44-4, CD44 transcript variant 4; CD44-5, CD44 transcript variant 5; 
IL-8, interleukin 8; IL-11, interleukin 11; PLAUR, plasminogen activator urokinase receptor; 
TFP12, tissue factor pathway inhibitor 2. 
 Average Value of Triplicate p Value 
 Cont D1 D3 D7 Cont vs D1 Cont vs D3 Cont vs D7 
CD44 -4 6.39 11.97 10.72 12.79 9.55E-08 6.16E-07 7.61E-08 
CD44-5 5.66 7.90 7.72 10.02 0.000149 6.61E-05 8.96E-08 
IL-11 5.75 7.77 7.10 8.16 8.80E-05 0.000715 3.62E-05 
Cyclin 
D1 
11.52 12.79 12.34 12.21 1.07E-06 1.51E-06 0.000248 
TFPI2 6.58 8.7 8.53 8.67 7.74E-05 1.11E-06 0.000336 
IL-8 5.61 6.29 5.68 7.23 8.66E-05 0.090 9.85E-05 
PLAUR 6.04 6.04 6.66 7.29 0.99 0.00037 0.000118 
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Figure 26. NFĸB pathway activation by serum-induction. Protein samples were 
obtained from GSC11 and GSC23 cells cultured in serum-free or serum-containing 
medium in the presence or absence of 20mM NAC for 3 days. The protein expression 
of phospho-IKBα, IKBα, phosphor-p65, p65 and β-actin was assayed by western blot.  
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Inhibition of NFĸB pathway prevents CD133 decrease and ANXA1 increase. 
An IKK inhibitor, BMS-345541 was used to inhibit the activation of NFĸB signaling 
in GSC11 cells. The western blot results showed the inhibition of NFĸB pathway in serum-
induced cells in a dose-dependent manner (Figure 27). 10 µM and 20 µM of BMS-345541 
prevented the decrease of CD133 and inhibited the ANXA1 increase (Figure 27). 
 
 
 
 
 
Figure 27. IKK inhibitor BMS-345541 prevents CD133 decrease and ANXA1 
increase.  GSC11 cells were cultured in serum-free or serum-containing medium 
with different dose of BMS345541 or 20mM of NAC. Cells were collected after 3 
days and the expression of phospho-IKBα, phosphor-p65, CD133, ANXA1 and β-
actin was assayed by western blot. 
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Serum induction promotes tumorigenesis and malignancy in vivo 
In order to test the effect of serum induction on tumor formation, we cultured the 
GSC11 cells under different conditions for 7 days and inoculated the same number of cells 
subcutaneously into the right flank of nude mice. Interestingly, the mice inoculated with 
serum-induced cells all formed tumors (Figure 28A). However, only 2 out of 7 mice treated 
with cells cultured in serum-free medium (the control group) formed tumors. There were 4 
mice in the NAC group and 5 mice in the serum plus NAC group formed tumors. The 
overall survival of the control group was significantly higher than the serum induction group, 
with a p value 0.0019 (Figure 28B). No significant difference of overall survival was found 
between the control group and NAC or serum plus NAC group. 
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Figure 28. Serum induction increases tumorigenicity and malignancy in GSCs. 
GSC11 cells were cultured under serum-free medium or serum-containing medium 
in the presence of absence of 20mM NAC for 7 days. 2X106 cells were inoculated 
subcutaneously into the right flank of each nude mouse. (A) Number of mice with 
visible tumors in each group. (B) Survival curves for the mice in each group. The 
mice were euthanized when the tumor diameter was greater than 20 mm. 
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CHAPTER 5 
Targeting metabolism with 3-BrOP and BCNU in GSCs 
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GSCs exhibit high glycolytic activity and resistance to TMZ and BCNU but sensitivity 
to glycolytic inhibition.  
GSC11 and GSC23 were cultured in the serum-free stem cell culture medium 
supplemented with EGF and bFGF. Under these culture conditions, the GSCs exhibited 
relatively low mitochondrial respiration as evidenced by a low oxygen consumption rate 
(Figure 29A).  When the cells were induced to undergo differentiation by exposure to serum, 
mitochondrial respiration was substantially activated leading to approximately 90% increase 
in oxygen consumption after 20 days (Figure 29A), accompanied by a decrease in lactate 
production (Figure 29C) and a significant decrease in glycolytic index (Figure 29D). This 
data suggests the GSCs maintained in their stem stage had a low mitochondrial respiration 
and high glycolytic activity, and serum induction activated mitochondrial oxidative 
phsophorylation and reduced the need of glycolysis for energy production.   
When GSC11 and GSC23 cells were treated with TMZ and BCNU for 72 hours, two 
drugs commonly used in the treatment of glioblastoma, the cells showed resistance to these 
conventional chemotherapeutic drugs.  The MTS assay demonstrated that GSCs were more 
resistant to TMZ and BCNU under hypoxic conditions than under normoxic conditions 
(Figure 30). In contrast, GSCs were also sensitive to 3-BrOP under hypoxic conditions, with 
the similar or lower 50% inhibitory concentrations than those under normoxic conditions. 
These data are consistent with the observation that GSCs had low mitochondrial function 
and thus were more dependent on glycolysis, which was inhibited by 3-BrOP, a derivative 
of the alkylating agent 3-bromopyruvate known to inhibit two major glycolytic enzymes 
hexokinase II and GAPDH (74, 86, 187, 188).  
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Figure 29. Serum induction causes decrease of glycolysis. (A) Comparison of 
oxygen consumption in GSC11 cells before and after exposure to serum for 20 days. 
Oxygen consumption was measured using an Oxytherm system as described in 
Methods. *, P<0.05. (B) Comparison of glucose uptake in GSC11 cells before and 
after exposure to serum for 20 days. (C) Lactate generation rates in GSC11 cultured in 
GSC medium and in serum-containing medium for 20 days. *, P<0.05; **, P<0.01. (D) 
Comparison of glycolytic index in GSC11 cells and serum-induced differentiated cells. 
**, P<0.01. Glycolytic index was calculated according to the formula (L × G)/O, in 
which L is the cellular lactate production, G is the glucose uptake, and O is the oxygen 
consumption rate. 
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Figure 30. GSCs are resistant to chemotherapeutic agents but sensitive to 
glycolytic inhibitor 3-BrOP. Sensitivity of GSCs to TMZ, BCNU, and 3-BrOP 
under hypoxic and normoxic conditions. GSC11 or GSC23 cells were incubated 
with the indicated concentrations of drugs for 72 h, and cell viability was measured 
by MTS assay. 
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Combination of 3-BrOP and BCNU shows synergistic effect in killing GSCs, especially 
under hypoxic conditions 
We then tested if a combination of 3-BrOP with BCNU or TMZ can lead to more 
effective killing of GSCs, based on the postulation that 3-BrOP would deplete the cellular 
ATP by inhibiting glycolysis and thus impair the ability of cells to repair DNA damage 
induced by BCNU or TMZ. The results showed that 3-BrOP substantially potentiates the 
killing effect of BCNU but not TMZ, especially under hypoxic conditions (Figure 31A-C). 
Treatment with the combination of 10 µM 3-BrOP and 50 µM BCNU inhibited cell growth 
by 50% in GSC11 cells (Figure 31A) and GSC23 cells (Figure 31B), whereas treatment with 
either drug alone only slightly inhibited cell growth. We further confirmed the synergistic 
killing effect of the 3-BrOP and BCNU combination using annexin-V/PI staining.  Most 
GSC11 cells were killed after 24 hours of treatment with 200 µM BCNU in combination 
with 15 µM 3-BrOP, whereas we did not observe significant cell death with treatment with 
either drug alone (Figure 31C). Similar results were also observed in GSC23 cells (Figure 
33A). The combination index (CI), which was calculated according to various 
concentrations of 3-BrOP and BCNU treatments (Table 6), was between 0.701~0.979, 
suggesting a synergistic effect (CI<1) of BCNU and 3-BrOP. The cell-death pattern was 
primarily necrosis, which suggests that the ATP-dependent apoptosis process was hampered 
due to ATP depletion induced by 3-BrOP. The synergistic killing effects of BCNU and 3-
BrOP were more dramatic in hypoxia than in normoxia, as GSCs were more dependent on 
glycolysis for ATP generation under hypoxia. This finding suggests that 3-BrOP could be an 
effective therapeutic agent to target GSCs in hypoxic tissue environments. 
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Figure 31. Effective killing of glioblastoma stem cells by combination of 3-BrOP 
and BCNU. (A) Inhibition of GSC11 cells by BCNU (left panel), TMZ (right panel), 
or their combination with 3-BrOP (72 h MTS assay under hypoxic conditions). (B) 
Inhibition of GSC23 cells by BCNU (left panel), TMZ (right panel), or their 
combination with 3-BrOP (72 h MTS assay under hypoxic conditions). (C) Induction 
of cell death in GSC11 cells treated with BCNU, 3-BrOP, or their combination. Cell 
were incubated with the indicated concentrations of compounds for 24 h under 
normoxic and hypoxic conditions, and cell viability was measured using annexin-V/PI 
double staining followed by flow cytometric analysis.  
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  Table 6. 3-BrOP and BCNU have synergistic effect in killing GSCs. CI was calculated 
using Calcusyn software, according to the results of flow cytometric analysis in GSC11 cells 
treated with BCNU, 3-BrOP alone or in combination for 24 hours in hypoxic conditions. 
Combination Index (CI) of BCNU and 3-BrOP 
BCNU(µM) 3-BrOP(µM) CI 
100 10 0.979 
100 15 0.780 
100 20 0.883 
200 10 0.701 
200 15 0.710 
200 20 0.789 
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In vitro clonogenicity is considered as an indicator of the tumor-initiating capability 
of cancer cells in vivo. To assess the drug effect on clonogenicity of GSCs, we treated them 
with BCNU and 3-BrOP alone or in combination for 3 hours and then evaluated their 
clonogenicity using a neurosphere-forming assay. The neurosphere-formation ability of 
GSCs decreased slightly when treated with 50µM BCNU or 15µM 3-BrOP alone. However, 
combination of both compounds almost completely abolished the ability of GSCs to form 
neurospheres (Figure 32A). The quantitation of the spheres is shown in Figure 32B. These 
results indicate that GSCs underwent irreversible loss of ability to form spheres despite a 
short-term combination treatment (BCNU and 3-BrOP) followed by a period of drug-free 
incubation to allow for potential recovery. 
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Figure 32. Effect of BCNU, 3-BrOP, or their combination on neurosphere 
formation in GSCs. Pictures and quantitation of GSC11 neurospheres after incubated 
with the indicated concentration of drugs for 3 hours, and then cultured in drug-free 
stem cell medium for 3 weeks. 
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3-BrOP in combination with BCNU preferentially kills tumor cells with relatively low 
toxic effect on normal human astrocytes  
Since 3-BrOP inhibit the glycolytic pathway, and cancer cells, especially GSCs, are 
more dependent on this metabolic pathway to generate ATP, we hypothesized that inhibition 
of glycolysis by 3-BrOP would preferentially deplete ATP in GSCs and other cancer cells, 
but the non-malignant cells such as normal human astrocytes (NHAs) would be less 
sensitive to such inhibition. Indeed, as shown in Figure 33, a combination of sub-toxic 
concentrations of 3-BrOP and BCNU synergistically killed GSC23 cells (Figure 33A), the 
serum-induced GSC11 cells (Figure 33B), and the human glioma cell line U87 cells which 
were maintained in serum-containing conditions (Figure 33C). However, this drug 
combination caused only minimum cytotoxicity in the immortalized NHAs (Figure 33D). 
These observations suggest that normal human cells are fundamentally different from 
malignant cells in their energy metabolism and sensitivity to glycolytic inhibitor, and thus 
provide a therapeutic window for selectivity.  
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Figure 33. Preferential killing of glioblastoma cells by 3-BrOP and BCNU. The 
cytotoxic effect of 3-BrOP, BCNU, or their combination was compared in (A) 
GSC23 cells, (B) serum-induced GSC11 cells, (C) U87 glioma cells, and (D) the 
normal human astrocytes (NHA). Cells were incubated with the indicated drugs for 
24 h under hypoxia, and cell viability was measured by annexin-V/PI double 
staining followed by flow cytometric analysis. 
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Severe depletion of cellular ATP by 3-BrOP and BCNU in GSCs prior to cell death 
Based on the observations that GSCs were highly dependent on glycolysis for ATP 
generation, we hypothesized that inhibition of glycolysis by 3-BrOP would severely deplete 
ATP in GSCs. We first tested the effect of 3-BrOP or its combination with BCNU on 
glycolysis in GSCs, using lactate production as an indicator of glycolytic activity. As shown 
in Figure 34A, a 3-hour incubation of GSC11 cells with 100-200 µM BCNU or 15-20µM 3-
BrOP alone caused only slight inhibition of lactate production, and the combination of these 
two compounds showed significant inhibition (Figure 34A), leading to a substantial decrease 
of cellular ATP by more than 50% (Figure 34B). A prolonged incubation with both 
compounds for 6 hours in hypoxia led to massive depletion of ATP (Figure 34C). It is worth 
noting that incubation with 200 µM BCNU or 15 µM caused a slight reduction of ATP by 
10% and 30%, respectively, while the combination of these two compounds led to more than 
90% ATP depletion (Figure 34C).  Similar effect of 3-BrOP and BCNU in causing ATP 
depletion was also observed in GSC23 (Figure 34D).  Interestingly, incubation of GSC cells 
with TMZ did not cause any significant change in ATP, and this compound did not enhance 
the ability of 3-BrOP to induce ATP depletion (Figure 35). This might explain why 
treatment of GSCs with 3-BrOP plus TMZ did not show any enhancement of cytotoxicity. 
Flow cytometric analysis of cell viability showed that GSC cells treated with 3-BrOP plus 
BCNU remained largely viable at both the 3-hour and 6-hour time points (Figure 34E), 
suggesting that the observed ATP depletion was an early event and was not a consequence 
of cell death.   
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Figure 34. Effect of 3-BrOP and BCNU on energy metabolism in glioblastoma 
stem cells. (A) Inhibition of lactate production in GSC11 cells by the indicated 
concentrations of BCNU and 3-BrOP (3 h, hypoxia). *, P<0.05; ***, P<0.001. (B) 
ATP depletion in GSC11 cells by the indicated concentrations of BCNU and 3-BrOP 
for 3 h under hypoxia. (C) ATP depletion in GSC11 cells by the indicated 
concentrations of BCNU and 3-BrOP for 6 h under hypoxia. (D) ATP depletion in 
GSC23 cells by the indicated concentrations of BCNU and 3-BrOP for 3 h under 
hypoxia. (E) Viability of GSC11 cells after incubation with 3-BrOP and BCNU for 3 
h or 6 h under hypoxic conditions. Cell viability was measured by annexin-V/PI 
double staining followed by flow cytometric analysis. 
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Figure 35. Effect of 3-BrOP and TMZ on ATP generation in glioblastoma stem 
cells. ATP generation in GSC11 cells by the indicated concentrations of BCNU and 
TMZ for 3 hours (A) or 6 hours (B) under hypoxia. ATP generation in GSC23 cells 
by the indicated concentrations of BCNU and TMZ for 3 hours (C) or 6 hours (D) 
under hypoxia.  
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Inhibition of GAPDH enzyme activity by BCNU and 3-BrOP 
The observation that BCNU but not TMZ was able to potentiate the ability of 3-
BrOP to deplete ATP led us to speculate that BCNU might have certain unique mechanism 
of action different from TMZ. This synergistic killing effect is a unique functional 
characteristic of BCNU. Since BCNU is known to inhibit glutathione reductase by 
alkylating its thiolate-active site (189), we speculated that it is possible that this compound 
might inhibit the glycolytic enzyme GAPDH, which also has potential thiolate-active site for 
alkylation by BCNU. To test this possibility, we assessed the GAPDH activity of GSCs after 
treatment with BCNU and 3-BrOP alone and in combination for 30 minutes, and the protein 
lysates were subjected to the assay for GAPDH activity. Interestingly, treatment with both 3-
BrOP and BCNU alone inhibited GAPDH activity by about 60% (Figure 36A), and 
treatment with the combination of the two inhibited GAPDH activity by almost 80%, which 
may explain why ATP was depleted dramatically in the combination setting. We further 
confirmed inhibition of purified GAPDH by BCNU and 3-BrOP at various concentrations 
using an in vitro enzymatic assay. The concentrations of BCNU and 3-BrOP required to 
inhibit the purified GAPDH activity by 50% were about 200 µM and 10 µM, respectively 
(Figure 36B-C). Incubation of purified GAPDH with the combination of BCNU and 3-BrOP 
in vitro resulted in further inhibition of GAPDH activity (Figure 36D). 
Similar to previous studies reported by Pereira da Silva’s group(86), we found that 
hexokinase II is not a prefererd target of 3-BrOP in GSCs. Specifically, we observed that the 
hexokinase II activity in GSC11 cells treated with 3-BrOP and BCNU at the same 
concentrations used in our GAPDH activity assay was not effectively inhibited. (Figure 36E). 
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We performed an in vitro enzymatic assay using purified hexokinase II and confirmed that 
the same concentrations of 3-BrOP as those used in our GAPDH activity assay could not 
effectively inhibit hexokinse activity and that concentrations as high as 300µM could inhibit 
it by only 20% (Figure 36F). We observed no significant differences in the inhibition of 
purified hexokinase activity in groups of GSCs incubated with BCNU and 3-BrOP alone or 
in combination at different concentrations in vitro (data not shown). 
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Figure 36. Inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by 
BCNU and 3-BrOP. (A) Effect of BCNU (BC) and 3-BrOP (Br) on GAPDH enzyme 
activity in GSC11 cells. Cells were first incubated with the indicated concentrations of 
BCNU or 3-BrOP for 30 min, and protein extracts were prepared for analysis of 
GAPDH activity without further addition of the compounds in vitro. (B) Inhibition of 
purified GAPDH enzyme by BCNU in vitro. (C) Inhibition of purified GAPDH 
enzyme by 3-BrOP in vitro. (D) Inhibition of purified GAPDH enzyme by combination 
of BCNU and 3-BrOP in vitro. (E) Hexokinase II activity of GSC11 cells after 30min 
treatment with indicated concentrations of BCNU, 3-BrOP alone and combinations. (F) 
Enzymatic activity inhibition of purified hexokinase II after 30min in-vitro incubation 
with serial concentrations of 3-BrOP.  
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3-BrOP impairs the ability of GSCs to repair BCNU-induced DNA damage  
BCNU can cause DNA damage by formation of DNA monoadducts and also cause 
inter-strand cross-links and double-strand breaks (DSBs) in DNA (190, 191).  DSBs are 
repaired in mammalian cells by nonhomologous end-joining and homologous recombination 
repair after DNA damage (192), in which γH2AX formation is a rapid, sensitive cellular 
response to the presence of DSBs (193). Since ATP is required for H2AX phosphorylation 
and the subsequent complicated DNA repair process, we hypothesized that dramatic 
depletion of the ATP pool in GSCs could compromise the DNA-repair process, rendering 
GSCs unable to undergo DNA replication and ultimately leading to cell death. Using a 
comet assay, we observed that treatment with BCNU alone or combination with 3-BrOP for 
6 hours caused severe DNA damage in GSCs, resulting in the appearance of broken DNA as 
the comet tails after single cell electrophoresis (Figure 37A).  In GSCs treated with BCNU 
alone, the DNA damage could be repaired 3-6 hours after the removal of BCNU, as 
evidenced by the disappearance or reduction of the DNA tails (Figure 37A-B). However, the 
GSCs were unable to repair the DNA damage in GSCs treated with the combination of 
BCNU and 3-BrOP, as the DNA tails persisted after drug removal and the cells were 
incubated in fresh medium (Figure 37A).  In fact, the percentage of DNA in the tails 
increased from 50% to 60% after 3-hour recovery and to more than 80% after 6-hour 
recovery in GSCs treated with the drug combination (Figure 37B). Using flow cytometry, 
we confirmed that the cell death in the combination treatment setting was irreversible even 
after 18 hours of recovery in fresh medium (Figure 37C). 
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Figure 37. 3-BrOP inhibits the repair of BCNU-induced DNA damage. (A) Comet 
assay of DNA damage in GSC11 cells treated with BCNU, 3-BrOP, or their 
combination. Cells were treated with the indicated concentrations of compounds for 6 
hours, and then either immediately processed for comet assay or cultured in drug-free 
medium for additional 3-6 hours for potential DNA repair. The bright green dots 
represent the positions of cellular nuclei; the “tail” length and intensity and on the right 
side of each nucleus represent the degree of DNA strand breaks eluted out from the 
cell during electrophoresis. (B) Quantification of DNA damage in GSC11 cells treated 
with or without BCNU and 3-BrOp as indicated. At least 30 cells in each sample were 
quantitatively analyzed for % of DNA tail that eluted from the cellular nuclei. *, 
P<0.05; **, P<0.01; ***, P<0.001. (C)Flow cytometric analysis (annexin-V/PI 
staining) was also used to measure cell death at 24 h (18 h after drug removal).  
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γH2AX is a commonly used marker for DNA DSB repair. Immediately after 
formation of DSBs, the MRN complex (MRE11, RAD50, and NBS1) binds to broken DNA 
ends and recruits active ATM, ATR, and/or DNA-PK, resulting in phosphorylation of the 
subtype of histone H2A, called H2A, in the position of Ser 139 (γH2AX) and initiation of 
the DNA-repair process (194), and dephosphorylation and removal of γH2AX in the cancer 
cells has been shown to be a significant step toward turning off the DNA damage response 
(195).  In our study, we observed that when GSCs were incubated with BCNU for 4 hours, 
both single-agent and combination treatment induced a large increase in γH2AX. When we 
continuously treated GSCs for 6 hours, we observed that the DNA damage and active repair 
were ongoing in the BCNU-alone group, whereas it was almost turned off with 
dephosphorylation of H2AX in the combination group. As shown in Figure 38, the blotting 
of γH2AX decreased. This was consistent with our results above indicating that maximum 
ATP pool drainage in GSCs occurred after 6 hours of treatment with the combination of 3-
BrOP and BCNU.  
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Figure 38. Effect of 3-BrOP and BCNU on H2AX phosphorylation. Western 
blot analysis of γH2AX and total H2AX protein in GSC11 cells treated with the 
indicated compounds for 2, 4 or 6 hours. BC, BCNU; Br, 3-BrOP. 
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3-BrOP and BCNU decrease tumorigenicity in vivo. 
Since we observed that the combination of 3-BrOP and BCNU completely abolished 
the ability of GSCs to form neurospheres in vitro, we further tested the effect of 3-BrOP and 
BCNU on tumorigenicity in vivo by inoculating the cells into mice brain in cooperation with 
Dr Xiao-nan Li’s lab. GSC11 cells were grown in serum-free medium and treated with PBS 
(control), 20µM of 3-BrOP, 20µM of BCNU and the combination of 3-BrOP and BCNU for 
6 hours.  The same amount of cells was inoculated into mice brain. All mice in control, 3-
BrOP or BCNU group died. But only two out of five mice in the group treated with 20µM 3-
BrOP and 20µM BCNU had died (Figure 39). The survival curve showed that the mice in 
the combination group live significantly longer than the control group (p=0.0027) and the 
BCNU group (p=0.012).  
 
 
 
Figure 39. Effect of 3-BrOP and BCNU on mice survival. GSC11 cells were 
treated with PBS (control), 20µM of 3-BrOP, 20µM of BCNU and the combination of 
3-BrOP and BCNU for 6 hours and inoculated orthotopically into mice. 
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Glioblastoma stem cells are held to be responsible for tumor initiation, progression 
and recurrence due to resistance to treatments.  Therefore, an improved understanding of the 
mechanisms how GSCs maintain their stemness is crucial for designing new therapeutic 
strategies for targeting GSCs. This study provided mechanistic and functional evidence that 
mitochondrial ROS is important in triggering GSCs aberrant differentiation and GSCs rely 
more on glycolytic metabolism than bulk tumor cells. By treating GSCs with a glycolytic 
inhibitor 3-BrOP and a standard chemotherapeutic agent, BCNU, we identified a novel 
therapeutic strategy to kill the GSCs that are resistant to conventional drug. 
ROS trigger GSC aberrant differentiation 
It has been known for some time that cancer stem cells, similar to normal stem cells, 
require certain tissue microenvironment to maintain their stemness (76, 196), and exposure 
of stem cells to serum in vitro usually induces differentiation with a loss of self-renewal 
capacity (94). However, the specific serum factors that induce differentiation and the 
underlying mechanisms remain unclear. Our study revealed a ROS-mediated mechanism by 
which serum induces GSC differentiation. We found that exposure of glioblastoma stem 
cells to serum activated mitochondrial respiration, leading to an increase of oxygen 
consumption and an increase in generation of mitochondrial O2-, which induced the 
expression of SOD2 to convert O2- to H2O2. Owing to its relatively long half-life and ability 
to diffuse across biological membranes, H2O2 has been considered as a second messenger 
that mediates redox-sensitive signaling in cellular response to growth factors (197, 198).  
The ability of H2O2 to cause oxidation of protein thiol via catalytic cysteine can alter the 
function of the target proteins, and thus provides a mechanism for redox signaling (198). 
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Since superoxide has an extremely short half-life and cannot pass the mitochondrial 
membranes, the increased O2- within the mitochondria could not directly function as a 
second messenger to affect the nuclear gene expression. As such, conversion of the 
mitochondrial O2- to H2O2 by SOD2 seems important to relay the redox signal from 
mitochondria to cytosol and nucleus during serum-induced differentiation of GSCs. The 
upregulation of SOD2 in serum-treated GSCs would facilitate the conversion of O2- to H2O2.  
Previous studies suggest that breast CSCs retain low levels of ROS, which lead to 
less DNA damage and contribute to their resistance to radiation (46). Drug-tolerant stem-
like breast cancer cells show lower levels of ROS and an increase in antioxidant enzymes 
compared with the parental untreated cells (199). Additionally, tumor sample tissues from 
patients pre-treated with chemotherapy drugs also show lower levels of ROS and enhanced 
expression of superoxide dismutase compared with the tumor tissues from patients that don’t 
receive any chemotherapy (199).  Our study confirmed that CSCs maintain a low redox 
status by comparing the GSCs to their aberrant differentiated counterparts. Under serum 
induction, the GSCs upregulate their mitochondrial ETC function, which triggers the 
transition of mitochondria from low function into activation and results in an increase of 
mitochondrial ROS. These results may explain the phenomenon that CSCs have lower ROS 
than non-stem cancer cells. The correlation between mitochondrial function and the 
regulation of CSCs has been found in glioma. Inhibition of ETC by a complex I inhibitor 
rotenone or long-term treatment with low doses of ethidium bromide to deplete 
mitochondrial DNA (ρ0 cells) enriched CD133+ cells (83). The ρ0 cells lacking a functional 
electron transport chain developed enhanced anchorage-independent growth and increased 
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invasion phenotypes (83). However, our results showed that the mitochondrial ROS instead 
of ETC itself is important in triggering serum-induced aberrant differentiation.  
Although the ability of ROS to induce stem cell differentiation has been noticed in 
some experimental systems (200), the exact mechanisms remain unclear. Our study suggests 
that the down regulation of SOX2, Olig2, and the Notch-related molecules by ROS might be 
a potential mechanism. Since SOX2, Olig2, and the Notch pathway are involved in 
promoting neural stem cells function (201, 202), down regulation of these genes would lead 
to a loss of stemness and promote differentiation.  It is possible that the expression of SOX2, 
Olig2, and the Notch-related molecules are regulated via a redox-sensitive mechanism, with 
ROS being a negative regulator. The ability of exogenous antioxidant NAC to prevent the 
decreased expression of these genes and to block the serum-induced differentiation 
phenotype supports this notion. CSCs may maintain their ROS at a low status through 
expressing some special molecules. For instance, CD44, a widely used CSC marker, was 
recently found to contribute to ROS defense by stabilizing a glutamate-cystine transporter, 
xCT, and promoting the synthesis of GSH (154).  
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The effects of ROS on the GSC aberrant differentiation are likely mediated by NFĸB 
NFĸB signaling pathway plays a crucial role in cancer development and progression 
(203). It can either promote or inhibit carcinogenesis, depending on the cell type in which it 
acts. The NFκB transcription factors are assembled through dimerization of five subunits, 
namely p65 (RelA), v-rel reticuloendotheliosis viral oncogene homolog B (RelB), c-Rel, 
p50 (NFκB1) and p52(NFκB2) (204). The five subunits share the same DNA binding 
domain, Rel homology domain. Prior to cell stimulation, the majority of NFκB subunits are 
kept in the cytoplasm by a family of proteins called IκBs that prevent NFκB’s binding to 
DNA. Activated IκB kinase (IKK) phosphorylates IκBs and triggers their degradation and 
the nucleus translocation of NFκB. NFĸB signaling pathway is often activated by ROS 
through IĸB or IKK phosphorylation (205). This study found that serum could cause the 
activation of NFκB which could be blocked by the antioxidant NAC. These results suggest 
that the activation of NFĸB in the serum-induced cells is probably caused by the ROS 
increase (Figure 40). It’s worth noting that deletion of NFĸBIA which encodes the NFĸB 
inhibitor IĸBα is a frequent oncogenic event in GBM (206). NFĸB activation is also 
involved in the formation of breast cancer stem cells in response to transient activation of 
Src oncoprotein (207). Our observation that NFĸB is activated in glioblastoma-initiating 
cells after induction of differentiation by FBS was also confirmed by Nogueira et al (208). 
Since NFĸB plays a crucial role not only in neural stem cell differentiation but also in brain 
cancer stem cells (208, 209), it is probably the signaling pathway which connects serum-
induced ROS increase with the aberrant differentiation of glioblastoma stem cells. We have 
found a selective IKK1 and IKK2 inhibitor BMS-345541 can protect the decrease of a stem 
cell marker CD133 and prevent the increase of a differentiation marker ANXA1 (210). 
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However, the underlying mechanism of how NFĸB pathway affects GSC differentiation still 
needs to be further clarified.  
Interestingly, although the serum induction caused the aberrant differentiation of 
GSCs and the decreases of stem cell markers-CD133, SOX2 and Olig2, it led to an increase 
of tumorigenicity and a reduction of survival in mice. These results seem to jeopardize the 
conventional theory of cancer stem cells which holds that only CSCs have the ability to form 
tumor and they will lose the tumorigenicity once going to differentiation. It has been 
postulated that CSCs preferentially transplant disease and contribute disproportionately to 
tumor growth compared to more differentiated cells (211). However, a recent study found 
that tumor cell self-renewal doesn’t predict tumor growth potential (211). Glioma cells with 
low self-renewal capacity were more tumorigenic and generate tumor more rapidly than 
cells with high self-renewal capacity (211). Our results had similar observations and may 
provide a mechanistic interpretation of this phenomenon. The role of NFĸB pathway in 
normal stem cell proliferation has been identified. NFĸB is stimulated during human 
embryonic stem cell (hESC) differentiation and inhibition of NFĸB leads to a reduction of 
hESC proliferation and suppression of differentiation toward all primitive extraembryonic 
and embryonic lineages with the exception of primitive ectoderm and ectodermal lineages 
(204). Whether the NFĸB signaling has a similar role in CSCs still needs to be elucidated. 
If NFĸB is the crucial pathway in promoting CSCs proliferation and disease 
progression, targeting NFĸB will be effective in eradicating the CSCs. Several studies have 
shown that targeting NFĸB pathway can be effective in killing CSCs (212-214). Inhibition 
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of NFĸB through using compounds including niclosamide and disulfiram can kill AML stem 
cells and breast CSCs (212, 214).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40. ROS mediates serum-induced aberrant differentiation. GSCs have 
low mitochondrial function and rely more on glycolysis for energy production. 
Serum factors trigger the activation of mitochondrial function and electron transport 
chain, which leads to the ROS increase. The upregulation of ROS causes NFκB 
activation and results in cell proliferation and tumor progression. 
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Potential therapeutic importance of inducing differentiation in GSCs 
Cancer stem cells or tumor-initiating cells play a major role in drug resistance and 
disease recurrence owing to their high self-renewal capacity and the ability to repair DNA 
damage and export cytotoxic compounds (44, 45). The unique biological properties of 
cancer stem cells render them difficult to be eliminated in vivo using conventional therapies. 
The recognition of the important role of cancer stem cells in drug resistance has prompted 
recent search for new means to overcome this significant problem in cancer treatment. 
Because the stemness of cancer cells is critical for cancer development and disease 
recurrence, induction of cancer stem cell differentiation has been considered as a potential 
therapeutic strategy (215, 216). For example, all-trans-retinoic acid (ATRA) and arsenic 
trioxide have been shown to induce differentiation in acute promyelocytic leukemia and 
turned out to be effective in the treatment of this malignancy (217, 218). ATRA can induce 
differentiation and reduce tumorigenicity in stem-like glioma cells (219). Thus, 
identification of the key factors that induce cancer stem cells differentiation and elucidation 
of the underlying mechanisms could have significant implications in developing novel 
therapeutic strategies to impact CSCs and to improve the outcomes of cancer treatment.  Our 
study suggests that the cellular redox status may profoundly affect the fates of glioblastoma 
stem cells, and that modulation of mitochondrial function and ROS generation may be an 
effective way to impact CSCs. As such, induction of cancer stem cell differentiation by 
ROS-mediated mechanisms seems to add a new mean to the “radical” therapeutic 
approaches to cancer therapy (30).   
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The combination of 3-BrOP and BCNU exhibits a striking synergistic killing effect in 
GSCs. 
In the present study, we observed that GSCs had low mitochondrial respiration. 
Glycolysis serves as the major energy source for maintenance of CSC metabolism, survival, 
and self-renewal. An effective agent that targets glycolysis can achieve the goal of 
eliminating CSCs. A glycolytic inhibitor 3-BrOP shows its efficacy in killing the drug 
resistant GSCs. We postulated that ATP depletion induced by glycolytic inhibition could 
cause a severe energy crisis, which could lead to a severe compromise of GSC’s ability to 
repair DNA damage induced by chemotherapeutic agents (Figure 41). However, it seems 
that it is necessary to deplete ATP to certain level in order to effectively compromise the 
ability of DNA repair. In GSCs, this severe ATP depletion could be efficiently achieved by 
combination of 3-BrOP with BCNU, but not with TMZ. This is due to the ability of BCNU 
and 3-BrOP to inhibit GAPDH activity in a synergistic fashion. This finding raises a 
potential for use of this drug combination to eliminate GSCs and overcome the resistance of 
glioblastoma to chemotherapeutic drugs, especially under hypoxic conditions.  Almost all 
GSCs were effectively killed by this combination in 24 hours and a short term exposure to 
this drug combination that has not shown killing effect in vitro could already reduce GSCs’ 
tumorigenicity and prolong survival in mice.  
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Figure 41. The combination of 3-BrOP and BCNU induces cell death. On one 
hand, 3-BrOP can cause the decrease of ATP by inhibiting glycolysis and BCNU can 
induce further decrease of ATP probably through inhibiting GAPDH activity. On the 
other hand, BCNU causes DNA damage which needs ATP for repairing. While the 
ATP crisis makes the DNA repair system nonfunctional and results in constant DNA 
damage and cell death.  
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Patients with glioblastoma multiforme, the most aggressive primary brain tumor, 
have poor prognoses, and there have been only limited improvements of therapeutic 
outcomes and patient overall survival over the past two decades, although multidisciplinary 
therapies for this cancer are performed (220). GSCs seem to reside in the niches where the 
cells are in hypoxic microenvironment, which contributes significantly to cancer 
chemoresistance and radioresistance (221). Although an increase in drug dosage could 
increase the effective drug concentration in the brain to kill more cancer cells, this may also 
increase toxic side effect and thus limit its applications. Furthermore, GSCs may adapt 
quickly to drug treatment by expressing increasing numbers of drug efflux pumps, DNA 
repair proteins like O6-methylguanine-DNA methyltransferase, and antiapoptotic proteins. 
In the case of BCNU, this compound has a very short half-life and the drug become 
undetectable after 5 minutes of treatment (222). Also, BCNU penetration in the brain tissue 
occurs over only a very short distance, approximately 2 mm from the ependymal surface 
(223). Thus, achieving and maintaining effective high concentration of BCNU in the tumor 
tissue is difficult. For effective and selective killing of cancer cells, especially CSCs, 
determining the fundamental differences between cancer and normal cells is critically 
important. For example, the cell energy metabolism pathway has emerged as a potential 
candidate target for treatment of cancers. Multiple studies have confirmed that nutrient 
metabolism in cancer cells may be different from that in normal cells. As first proposed by 
Otto Warburg (157), cancer cells might rely more on glycolysis for metabolism and survival, 
and the mitochondria in these cells were functionally aberrant.  
The observation that BCNU inhibited GAPDH activity is a novel finding of this 
study, although the primary pharmacological action of BCNU has been traditionally 
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attributed to its nucleoprotein alkylation and inhibition of DNA synthesis and repair 
mediated by its active chloroethyl moieties (224). BCNU may covalently inactivate GAPDH 
activity by S-nitrosylation of cysteine thiols which are important for disulfide formation. 
Although GAPDH activity can be inhibited by 50% with 200µM BCNU alone, we observed 
only a moderate depletion of ATP after 6 hours of treatment with BCNU at this 
concentration. A possible explanation for the small ATP decrease could be that inhibition of 
glycolysis by BCNU might have been compensated by mitochondrial oxidative 
phosphorylation. This is in contrast to 3-BrOP, which seems to inhibit both glycolysis and 
mitochondrial respiration to a certain degree (86, 225, 226). This might explain why 3-BrOP 
could deplete ATP more efficiently than BCNU when each compound was used alone. 
Although hexokinase II has been considered a major target of 3-BrPA (174, 227-229), a 
recent study using HepG2 cells suggested that this compound might inhibit GAPDH activity 
more effectively (86). It is possible that the synergistic combination effect of 3-BrOP and 
BCNU observed in the present study might be due, at least in part, to the fact that both 
compounds inhibit the same glycolytic enzyme GAPDH.  The combination of sub-toxic 
concentrations of 3-BrOP and BCNU seems to be an optimum way to inhibit GAPDH and to 
achieve effective killing of GSCs with low toxicity to normal cells. This is largely due to the 
unique mechanisms of action of each compound and the biological properties of GSCs, 
which are highly dependent on glycolysis and thus sensitive to such metabolic intervention.  
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Future Perspectives 
Many questions regarding the mechanisms of how NFĸB pathway leads to serum-
induced GSC activation and whether the combination of 3-BrOP and BCNU is effective in 
vivo remain. We showed that serum could induce the activation of NFĸB pathway and NAC 
was able to inhibit this activation. It is important to test whether the NFĸB pathway is 
crucial for the serum-induced GSC activation. Ideally, key components of NFĸB pathway 
would be knocked down in GSCs and tumorigenicity of the cells would be tested to confirm 
that the NFĸB pathway trigger the GSC activation. Moreover, activators such as interleukin-
1 and TNFα would be used to activate the NFĸB in GSCs and their effects on tumorigenicity 
and malignancy would be assayed. Potentially, besides the NFĸB activation, the metabolic 
alteration caused by serum induction is also important in mediating GSC activation. ATP 
generation and metabolite intermediates as well as cell cycle change promote the malignant 
transition of GSCs. Alternatively; other pathways like JNK also play some role in GSC 
activation.  These possibilities should be explored in further detail.  
Another important question is whether the combination of 3-BrOP and BCNU is 
effective in vivo. Our results implicate therapeutic potential of the combination treatment.  
However, whether 3-BrOP can pass the blood brain barrier remains unknown. Implantable 
pump for drug delivery to the brain would be utilized to study the effect of 3-BrOP and 
BCNU combination in glioblastoma xenografts. The toxicities of this combination need to 
be investigated.  
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Conclusion 
My study demonstrates that GSCs have low mitochondrial function and depend on 
glycolysis for energy production. Activation of mitochondrial by factors like serum causes 
ROS increase which leads to the induction of differentiation (Figure 42). The transition from 
glycolysis to oxidative phosphorylation moves GSCs into an intermediate stage and causes 
tumor proliferation and progression. Targeting the glycolytic metabolism with 3-BrOP and 
BCNU can achieve a striking killing effect in GSCs. 
 
 
 
 
Figure 42. A schematic model representing the role of metabolism change in tumor 
development.  
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